Background/Aims Information about the association of glucagon-like peptide-1 receptor (GLP-1RA) with liver and non-liver complications is insufficient in patients with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD). We conducted a target trial emulation study to evaluate whether GLP-1RA decreases the risk of liver and non-liver outcomes.
Methods Patients with T2D and MASLD initiating GLP-1RA or dipeptidyl peptidase-4 inhibitor (DPP-4i) were included from 2013 to 2022 in Merative™ Marketscan® Research Databases. Primary outcomes included incidences of (1) hepatocellular carcinoma (HCC) and cirrhosis, and (2) cardiovascular disease (CVD), chronic kidney disease (CKD), and non-liver cancer. Inverse probability of treatment weighting was applied to balance baseline characteristics and Cox regression models were conducted to estimate hazard ratio (HR) and 95% confidence interval (CI).
Results In the intention-to-treat design, GLP-1RA, compared with DPP-4i, had a significantly lower incidence (per 1,000 person-years) of HCC (0.8 vs. 1.7; HR 0.53, 95% CI 0.39–0.71), of cirrhosis (29.3 vs. 32.9; HR 0.91, 95% CI 0.86–0.96), of CVD (57.2 vs. 73.9; HR 0.90, 95% CI 0.86–0.95), of CKD (4.5 vs. 6.8; HR 0.73, 95% CI 0.64–0.84), and of non-liver cancer (16.9 vs. 22.9; HR 0.82, 95% CI 0.77–0.89). In the per-protocol design, significant inverse associations for these study outcomes still were observed, with HR 0.60–0.77.
Conclusions In this emulated target trial of nationwide patients with T2D and MASLD, GLP-1RA use, when compared with DPP-4i, was associated with a significantly lower risk of liver and non-liver complications.
Citations
Citations to this article as recorded by
Evaluating causal protective effect of dual GLP-1R/GIPR agonists on MASLD: A Mendelian randomization and colocalization study Yangke Cai, Siyuan Xie, Liyi Xu, Jiamin Chen, Jianting Cai European Journal of Pharmacology.2025; 1005: 178088. CrossRef
Impaired Thyroid Hormone Sensitivity is Associated with Increased
Risk of Liver Fibrosis in Euthyroid Population: A Cross-Sectional Analysis of
NHANES Xingyu Yao, Kaiwen Xiao, Hein Ko Oo Hormone and Metabolic Research.2025; 57(09): 511. CrossRef
Background/Aims Given the increase in prevalence of metabolic diseases, we investigated their long-term impacts on the outcomes of chronic hepatitis B (CHB) patients receiving nucleos(t)ide analogue (NA) treatment.
Methods We analyzed data from CHB patients for whom initiated NA treatment from 30 centers. We balanced patient characteristics with and without metabolic disease (diabetes, obesity, dyslipidemia, and hypertension) via propensity-score matching (PSM) to evaluate adverse outcomes.
Results The study included 4,500 patients. PSM yielded 909 pairs of patients with balanced characteristics. When stratified by the number of metabolic diseases, only patients with ≥2 metabolic diseases had an increased cumulative incidence of cirrhosis and overall death. However, when stratified by the presence of diabetes (regardless of the presence or number of other metabolic diseases), patients with diabetes (versus those without) had a significantly higher cumulative incidence of all outcomes: cirrhosis (P=0.009), hepatocellular carcinoma (HCC, P=0.023), and overall, liver-related, and non-liver-related death (P<0.001, P=0.026 and P<0.001, respectively). Having ≥2 metabolic diseases was associated with cirrhosis, overall death, and non-liver-related death but not HCC or liver-related death, while diabetes was significantly associated with a higher risk of all outcomes: cirrhosis (hazard ratio [HR]=3.75, P=0.004), HCC (HR=2.02, P=0.020), and overall, liver-related, and non-liver-related death (HR=2.53, P<0.001; HR=2.65, P=0.016; HR=2.38, P<0.001).
Conclusions Having two or more metabolic diseases was associated with a higher risk of cirrhosis, overall death, and non-liver-related death, but having diabetes as a single metabolic disease was significantly associated with all adverse outcomes including cirrhosis, HCC, and overall, liver-related, and non-liver-related death.
Citations
Citations to this article as recorded by
Advancing metabolic risk profiling in chronic hepatitis B: Reply to correspondence on “Metabolic health in antiviral era of chronic hepatitis B” Shang-Chin Huang, Jia-Horng Kao Clinical and Molecular Hepatology.2026; 32(1): e117. CrossRef
Metabolic health in antiviral era of chronic hepatitis B: Editorial on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues” Shang-Chin Huang, Jia-Horng Kao Clinical and Molecular Hepatology.2026; 32(1): 423. CrossRef
Differential HCC risk among HBV indeterminate types at baseline and by phase transition Rui Huang, Huy N Trinh, Satoshi Yasuda, Angela Chau, Mayumi Maeda, Ai-Thien Do, Daniel Q Huang, Takanori Ito, Takashi Honda, Masatoshi Ishigami, Ritsuzo Kozuka, Carmen Monica Preda, Cheng-Hao Tseng, Sebastián Marciano, Pei-Chien Tsai, Dong Hyun Lee, Chris Gut.2025; 74(11): 1873. CrossRef
Type 2 diabetes mellitus as an independent predictor of significant fibrosis in treatment-naïve chronic hepatitis B patients with concurrent hepatic steatosis Jie Li, Liang Xu, Fajuan Rui, Sally Tran, Pei-Chien Tsai, Youwen Tan, Hidenori Toyoda, Qing-Lei Zeng, Huy Trinh, Yao-Chun Hsu, Tsunamasa Watanabe, Hiroshi Abe, Hiroyuki Motoyama, Yoko Yoshimaru, Takanori Suzuki, Taeang Arai, Masanori Atsukawa, Phillip Vut Hepatology.2025;[Epub] CrossRef
Incidence and determinants of achieving HBsAg <100 IU/mL in HBeAg-negative CHB patients with nucleos(t)ide analogue treatment Jian Wang, Tao Fan, Zhiyi Zhang, Li Zhu, Shaoqiu Zhang, Ye Xiong, Chun Shan, Chao Jiang, Shengxia Yin, Xin Tong, Renling Yao, Juan Xia, Xiaomin Yan, Yu Shi, Yuxin Chen, Xingxiang Liu, Huali Wang, Haixia Zhang, Chuanwu Zhu, Qun Zhang, Chao Wu, Rui Huang Emerging Microbes & Infections.2025;[Epub] CrossRef
Impact of metabolic dysfunction on treatment responses to nucleos(t)ide analogues in chronic hepatitis B: a retrospective multi-center REAL-B cohort study Rui Huang, Dae Won Jun, Hidenori Toyoda, Yao-Chun Hsu, Huy Trinh, Akito Nozaki, Toru Ishikawa, Tsunamasa Watanabe, Haruki Uojima, Daniel Q. Huang, Takashi Honda, Yasuhito Tanaka, Philip Vutien, Sebastián Marciano, Hiroshi Abe, Masaru Enomoto, Masanori Ats eClinicalMedicine.2025; 87: 103407. CrossRef
Aspirin Use and Risk of HCC and Gastrointestinal Bleeding in Patients With HBV‐Related Cirrhosis: A Landmark Analysis Mi Na Kim, Geun U. Park, Seng Chan You, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn Journal of Gastroenterology and Hepatology.2025; 40(11): 2750. CrossRef
Multifunctional Metal Composite Hydrogels for Diabetic Wound Therapy Shengnan Zhang, Hui Gao, Kevin H. Mayo, Jingang Mo, Le Deng Gels.2025; 11(12): 960. CrossRef
Background/Aims With the obesity pandemic, metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common liver disease and a leading cause of end-stage liver disease and liver-related deaths in the USA. Therefore, we aimed to compare the long-term outcomes of patients with MASLD and cirrhosis with and without bariatric surgery.
Methods Patients were retrospectively identified from the California Department of Healthcare Access and Information database, 2005 to 2019, for a population-based cohort study. Propensity score matching (PSM) was used to balance background risks between patients with cirrhosis who underwent bariatric surgery and those who did not. Overall, liver-related and non-liver-related mortality were analyzed.
Results Of 91,708 eligible patients with MASLD and cirrhosis, PSM yielded 2,107 patients who underwent bariatric surgery and 8,428 non-bariatric controls. Compared to matched controls, patients who underwent bariatric surgery had lower 5-year overall (24.9% vs. 37.1%; p<0.0001), liver-related (3.3% vs. 14%; p<0.0001), and non-liver-related mortality (22.3% vs. 26.9%; p=0.046). In multivariable analysis, bariatric surgery was associated with decreased overall mortality (adjusted hazard ratio [aHR]=0.63; p<0.0001), liver-related (aHR=0.24; p<0.0001), and non-liverrelated (aHR=0.81; p=0.0026) mortality. However, only laparoscopic surgeries were associated with lower overall mortality (aHR=0.39; p<0.0001) whereas open surgeries were associated with higher overall mortality (aHR=1.24; p=0.022).
Conclusions Patients with MASLD and cirrhosis who underwent bariatric surgery, specifically laparoscopic approaches, had significantly lower mortality risk than non-surgical counterparts.
Citations
Citations to this article as recorded by
Differential Characteristics and Survival Outcomes of Patients With Cirrhosis According to Underlying Liver Aetiology Yu Shi, Nicholas Chien, Ashley Fong, Vy H. Nguyen, Surya Teja Gudapati, Angela Chau, Sally Tran, Linda Henry, Ramsey Cheung, Changqing Zhao, Minjuan Jin, Mindie H. Nguyen Alimentary Pharmacology & Therapeutics.2025; 61(10): 1622. CrossRef
A leap in the dark: Bariatric surgery for treatment of metabolic dysfunction-associated steatotic liver disease related cirrhosis: Editorial on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic live Jing Zeng, Jian-Gao Fan Clinical and Molecular Hepatology.2025; 31(2): 610. CrossRef
Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis” Wei Wang, Yating Xie, Ailei Xu Clinical and Molecular Hepatology.2025; 31(2): e143. CrossRef
Advancing precision medicine in metabolic dysfunction-associated steatotic liver disease Bryan A. Priego-Parra, Rocío Gallego-Durán, Berenice M. Román-Calleja, José Antonio Velarde-Ruiz Velasco, Manuel Romero-Gómez, Jordi Gracia-Sancho Trends in Endocrinology & Metabolism.2025; 36(11): 1000. CrossRef
Correspondence to editorial on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis” Nicholas A. Rouillard, Linda Henry, Mindie H. Nguyen Clinical and Molecular Hepatology.2025; 31(2): e173. CrossRef
Reply to correspondence on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis” Jing Zeng, Jian-Gao Fan Clinical and Molecular Hepatology.2025; 31(2): e218. CrossRef
Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis” Weixiong Zhu, Xuefan Zeng, Zengxi Yang, Yusheng Cheng, Wence Zhou Clinical and Molecular Hepatology.2025; 31(3): e252. CrossRef
Association between body roundness index and risks of all-cause and cardiovascular mortality in adults with metabolic dysfunction-associated steatotic liver disease: NHANES 1999–2018 Yanshan Yi, Li Yang Frontiers in Nutrition.2025;[Epub] CrossRef
Letter to the editor on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis” Chi-Kuei Hsu, Po-Yu Huang, Chih-Cheng Lai Clinical and Molecular Hepatology.2025; 31(3): e247. CrossRef
Efficacy and Safety of Bariatric Surgery in Well-Compensated Liver Cirrhosis: A Systematic Review and a Single-Arm Meta-analysis Pandora Fonseca, Leonardo Pereira, João Gabriel Braga, Giovanna Macanhã Scremin, Luísa de Araujo, Julia Alves, Gabriel de França, Pedro Bregion, Rafael Rego, Maria Farias, Victor Ivano Obesity Surgery.2025; 35(10): 4246. CrossRef
Metabolic Dysfunction Associated to Steatotic Liver Disease: A Review Janna Vanessa Diaz Torres, Vanessa Rocío Villanueva Guerrero, Jennifer Patricia Vargas Gómez, Fredy Javier Pacheco Miranda, Lorena Rocío Orozco Álvarez, Joseph David León Insignares, Marian Mares, Héctor Mario Rodríguez Ortiz, Evelyn Mendoza-Torres Metabolic Syndrome and Related Disorders.2025; 23(10): 427. CrossRef
Endoscopic Bariatric Therapies for Metabolic Dysfunction-Associated Steatotic Liver Disease: Mechanistic Insights and Metabolic Implications Wissam Ghusn, Mira Sridharan, Rachel Fromer, Muhammet Ozdemir, Madeleine G. Haff, Eric J. Vargas Biomedicines.2025; 13(10): 2437. CrossRef
Michael H. Le, David M. Le, Thomas C. Baez, Hansen Dang, Vy H. Nguyen, KeeSeok Lee, Christopher D. Stave, Takanori Ito, Yuankai Wu, Yee Hui Yeo, Fanpu Ji, Ramsey Cheung, Mindie H. Nguyen
Clin Mol Hepatol 2024;30(2):235-246. Published online January 26, 2024
Background/Aims Nonalcoholic fatty liver disease (NAFLD) is associated with a multitude of adverse outcomes. We aimed to estimate the pooled incidence of NAFLD-related adverse events.
Methods We performed a systematic review and meta-analysis of cohort studies of adults with NAFLD to evaluate the pooled incidence of adverse events.
Results 19,406 articles were screened, 409 full-text articles reviewed, and 79 eligible studies (1,377,466 persons) were included. Mean age was 51.47 years and body mass index 28.90 kg/m2. Baseline comorbidities included metabolic syndrome (41.73%), cardiovascular disease (CVD) (16.83%), cirrhosis (21.97%), and nonalcoholic steatohepatitis (NASH) (58.85%). Incidence rate per 1,000 person-years for mortality included: all-cause (14.6), CVD-related (4.53), non-liver cancer-related (4.53), and liver-related (3.10). Incidence for liver-related events included overall (24.3), fibrosis progression (49.0), cirrhosis (10.9), liver transplant (12.0), and hepatocellular carcinoma (HCC) (3.39). Incidence for non-liver events included metabolic syndrome (25.4), hypertension (25.8), dyslipidemia (26.4), diabetes (19.0), CVD (24.77), renal impairment (30.3), depression/anxiety (29.1), and non-liver cancer (10.5). Biopsy-proven NASH had higher incidence of HCC (P=0.043) compared to non-NASH. Higher rates of CVD and mortality were observed in North America and Europe, hypertension and non-liver cancer in North America, and HCC in Western Pacific/Southeast Asia (P<0.05). No significant differences were observed by sex. Time-period analyses showed decreasing rates of cardiovascular and non-liver cancer mortality and increasing rates of decompensated cirrhosis (P<0.05).
Conclusions People with NAFLD have high incidence of liver and non-liver adverse clinical events, varying by NASH, geographic region, and time-period, but not sex.
Citations
Citations to this article as recorded by
Polyphenols and terpenoids derived from Ocimum species as prospective hepatoprotective drug leads: a comprehensive mechanistic review Amrita Chatterjee, Biswatrish Sarkar Phytochemistry Reviews.2025; 24(2): 2087. CrossRef
An updated overview on hepatocellular carcinoma in patients with Metabolic dysfunction-Associated Steatotic Liver Disease: Trends, pathophysiology and risk-based surveillance Angelo Armandi, Chiara Rosso, Gian Paolo Caviglia, Elisabetta Bugianesi Metabolism.2025; 162: 156080. CrossRef
Association between skeletal muscle mass to visceral fat area ratio and depression: A cross-sectional study based on the National Health and Nutrition Examination Survey Chenle Ye, Guangzhan Chen, Weikai Huang, Yuanrun Liu Journal of Affective Disorders.2025; 372: 314. CrossRef
Type 2 diabetes and the minor allele of PNPLA3 consistently identify high-risk metabolic dysfunction associated steatotic liver disease Zobair M. Younossi, J.Michael Estep, Sean Felix, Brian Lam, Zaid Younossi, Andrei Racila, Maria Stepanova Diabetes Research and Clinical Practice.2025; 219: 111960. CrossRef
Correlation between metabolic dysfunction-associated steatotic liver disease and subclinical coronary atherosclerosis in eastern China Guanghui Ma, Guohou Xu, Haixia Huang Diabetology & Metabolic Syndrome.2025;[Epub] CrossRef
A Novel Point-of-Care Prediction Model for Steatotic Liver Disease: Expected Role of Mass Screening in the Global Obesity Crisis Jeayeon Park, Goh Eun Chung, Yoosoo Chang, So Eun Kim, Won Sohn, Seungho Ryu, Yunmi Ko, Youngsu Park, Moon Haeng Hur, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim Gut and Liver.2025; 19(1): 126. CrossRef
Letter to the editor on “Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis” Xiao-Song Li, Xi-Ping Shen, Hang Li Clinical and Molecular Hepatology.2025; 31(1): e15. CrossRef
PNPLA3 is one of the bridges between TM6SF2 E167K variant and MASLD: Correspondence to editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD” Baokai Sun, Likun Zhuang Clinical and Molecular Hepatology.2025; 31(1): e67. CrossRef
Metabolic dysfunction-associated steatotic liver disease and the cardiovascular system Antonis A. Manolis, Theodora A. Manolis, Apostolos Vouliotis, Antonis S. Manolis Trends in Cardiovascular Medicine.2025; 35(4): 258. CrossRef
KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025 Won Sohn, Young-Sun Lee, Soon Sun Kim, Jung Hee Kim, Young-Joo Jin, Gi-Ae Kim, Pil Soo Sung, Jeong-Ju Yoo, Young Chang, Eun Joo Lee, Hye Won Lee, Miyoung Choi, Su Jong Yu, Young Kul Jung, Byoung Kuk Jang Clinical and Molecular Hepatology.2025; 31(Suppl): S1. CrossRef
Association Between Handgrip Strength and Cardiovascular Disease Risk in MASLD: A Prospective Study From UK Biobank Tae Seop Lim, Sujin Kwon, Sung A. Bae, Hye Yeon Chon, Seol A. Jang, Ja Kyung Kim, Chul Sik Kim, Seok Won Park, Kyoung Min Kim Journal of Cachexia, Sarcopenia and Muscle.2025;[Epub] CrossRef
Underrepresentation of Asians in diagnostic test development and drug trials in MASLD Lung-Yi Mak, Terry Cheuk-Fung Yip, Chi-Ho Lee, Jimmy Che-To Lai, Vincent Wai-Sun Wong Journal of Hepatology.2025; 83(1): e59. CrossRef
Mechanisms of hepatocellular carcinoma and cirrhosis development in concurrent steatotic liver disease and chronic hepatitis B Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto Clinical and Molecular Hepatology.2025; 31(Suppl): S182. CrossRef
Reply to correspondence on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023” Jeayeon Park, Su Jong Yu Clinical and Molecular Hepatology.2025; 31(2): e221. CrossRef
Comprehensive Analysis Reveals the Molecular Features and Immune Infiltration of PANoptosis-Related Genes in Metabolic Dysfunction-Associated Steatotic Liver Disease Yan Huang, Jingyu Qian, Zhengyun Luan, Junling Han, Limin Tang Biology.2025; 14(5): 518. CrossRef
Association between dietary amino acid intake and the risk of metabolic dysfunction-associated steatotic liver disease Ruoqi Zhou, Xinrong Zhang, Xinxin Liu, Rui Huang, Yuwei Wang, Dajing Xia, Xue Li, Yihua Wu, Yu Shi Journal of Advanced Research.2025;[Epub] CrossRef
Young Adults With Metabolic Dysfunction–Associated Steatotic Liver Disease Have an Increased Risk of Early-Onset Cancer: A Nationwide Cohort Study Differentiating the Risk of 23 Site-Specific Cancers Joon Ho Moon, Seogsong Jeong, Heejoon Jang, Dong Hyeon Lee, Sae Kyung Joo, Bo Kyung Koo, Qiang Xia, Meng Sha, Yoosoo Chang, Won Kim Clinical Gastroenterology and Hepatology.2025; 23(13): 2540. CrossRef
Projected Trends in Metabolic Dysfunction–Associated Steatotic Liver Disease Mortality Through 2040 Xinrong Zhang, Sovann Linden, Charles R. Levesley, Xinyuan He, Zhanpeng Yang, Scott D. Barnet, Ramsey Cheung, Fanpu Ji, Mindie H. Nguyen JAMA Network Open.2025; 8(6): e2516367. CrossRef
Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association Kenneth Cusi, Manal F. Abdelmalek, Caroline M. Apovian, Kirthikaa Balapattabi, Raveendhara R. Bannuru, Diana Barb, Joan K. Bardsley, Elizabeth A. Beverly, Karen D. Corbin, Nuha A. ElSayed, Scott Isaacs, Fasiha Kanwal, Elizabeth J. Pekas, Caroline R. Richa Diabetes Care.2025; 48(7): 1057. CrossRef
Validation of the FibroScan-AST (FAST) and Agile 3+ score in metabolic dysfunction-associated steatotic liver disease in a Russian cohort of patients V. P. Gomonova, K. L. Raikhelson, V. A. Kashchenko, A. V. Lodygin, V. E. Karev Meditsinskiy sovet = Medical Council.2025; (8): 134. CrossRef
Chronic Kidney Disease Risk Associated With Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Nationwide Cohort Study in Korea Dong Wook Kim, Minkook Son, Hye Jung Lee, Chi Hyeon Choi, Yeo Wool Kang, Sang Yi Moon, Myeongseok Koh, Jong Yoon Lee, Yang Hyun Baek, Won Suk An Hepatology Research.2025; 55(9): 1239. CrossRef
All-cause and disease-specific mortality in young adults with MASLD: A nationwide cohort study Jeayeon Park, Goh Eun Chung, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Kyungdo Han, Eun Ju Cho JHEP Reports.2025; 7(9): 101477. CrossRef
Correlation between gynecomastia and endocrine regulation in patients with metabolic dysfunction-associated fatty liver disease: A cross-sectional study Ming-Huang Zhang, Ning Meng, Kang-Hui Zhang, Jun-Kang Yu, Chen-Hao Huang, Shu Yang, Ding-Yi Zhu World Journal of Hepatology.2025;[Epub] CrossRef
Screening for MASLD in patients with type 2 diabetes: is an early diagnosis a good diagnosis? Chinonso Nwoguh, Christopher D Byrne, Tina Reinson, Ryan M Buchanan Expert Review of Gastroenterology & Hepatology.2025; 19(9): 941. CrossRef
Association between metabolic dysfunction-associated steatotic liver disease and cardiovascular disease: New perspectives Qinyi Zhou, Wang Liu, Dan Zhou, Yifang Zhang, Zhaobing Li, Zili Li, Xiaofeng Ma Medicine.2025; 104(33): e43952. CrossRef
Patatin-Like Phospholipase Domain-Containing Protein 3 (PNPLA3) rs738409 Variant and Non-Alcoholic Fatty Liver Disease Risk in Vietnamese Working-Age Adults: A Case-Control Study with Metabolic Insights Ha Nguyen, Duong Hoang Huy Le, Thinh Nguyen, Hung Cao Dinh, Tuan Nguyen Clinical and Experimental Gastroenterology.2025; Volume 18: 191. CrossRef
Effect of hypertension on long-term adverse clinical outcomes and liver fibrosis progression in MASLD Xiao-Dong Zhou, Li-You Lian, Qin-Fen Chen, Seung Up Kim, Terry Cheuk-Fung Yip, Salvatore Petta, Atsushi Nakajima, Emmanuel Tsochatzis, Junping Shi, Wah-Kheong Chan, Jérôme Boursier, Elisabetta Bugianesi, Yusuf Yilmaz, Hannes Hagström, Manuel Romero-Gomez, Journal of Hepatology.2025;[Epub] CrossRef
Acetyl-CoA Carboxylase Inhibitors for Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Nurina Hasanatuludhhiyah, Arifa Mustika, Viskasari P. Kalanjati, Muhammad Miftahussurur, Naoto Uemura Pharmaceuticals.2025; 18(9): 1276. CrossRef
Association Between Liver Fibrosis and Cause‐Specific Mortality in Japanese Patients With Biopsy‐Confirmed Metabolic Dysfunction–Associated Steatotic Liver Disease: A Prospective Cohort Study / Liver Fibrosis and Mortality in Japanese MASLD Kyoko Sakai, Toshihide Shima, Hirohisa Oya, Takahiro Miura, Shohei Amioka, Takahiro Nonaka, Shinsaku Fujiishi, Keiichiro Okuda, Kei Terasaki, Kohei Fukumoto, Yasuhide Mitsumoto, Masayuki Mizuno, Takeshi Okanoue Hepatology Research.2025;[Epub] CrossRef
The Mediating Role of Body Mass Index in the Association of Socioeconomic Status With Hepatic Steatosis and Liver Fibrosis: A Cross‐Sectional Study Based on NHANES 2021–2023 Zongnan Chen, Xiaoling Zhu, Juan Guo, Gang Ma, Abdelilah Arredouani International Journal of Endocrinology.2025;[Epub] CrossRef
Global burden of cirrhosis and other chronic liver diseases caused by specific etiologies from 1990 to 2021 Ying Zhang, Ming Luo, Yingzi Ming BMC Gastroenterology.2025;[Epub] CrossRef
Call to action: integrating steatotic liver disease into public health strategies in Canada Sahar Saeed, Jessica Burnside, Cindy Wen, Carmela Rapino, Keyur Patel, Alnoor Ramji, Mark Swain, Giada Sebastiani The Lancet Regional Health - Americas.2025; 52: 101278. CrossRef
County-Level Factors and Preventable Premature Liver Mortality in Metabolic Dysfunction–Associated Steatotic Liver Disease James M. Paik, Shira Zelber-Sagi, Annette Paik, Linda Henry, Yusuf Yilmaz, Mohamed El-Kassas, Saleh A. Alqahtani, Zobair M. Younossi JAMA Network Open.2025; 8(10): e2538385. CrossRef
Lean Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Wolf in Sheep's Clothing Xixi Fang, Chenhao Xu, Jun Lu, Runzhou Zhuang, Xiao Xu, Xuyong Wei Cell Biochemistry and Function.2025;[Epub] CrossRef
The Role of Metabolites in CSF on NAFLD Development: A Mendelian Randomisation Analysis Fang Liang, Tiegang Xiao, Bing Wang Endocrinology, Diabetes & Metabolism.2025;[Epub] CrossRef
Association between mental health and MASLD molecular insights through metabolomics Dashuai Yang, Nan Zhao, Wei Zhang, Shouxin Peng, Xian Qin, Wenzhi He Communications Medicine.2025;[Epub] CrossRef
Role of Saroglitazar in Improving Transient Elastography Parameters in Significant and Advanced Metabolic Dysfunction-Associated Steatohepatitis Manish C Kak Cureus.2025;[Epub] CrossRef
Steatotic liver disease: Know your enemies Lung-Yi Mak Clinical and Molecular Hepatology.2024; 30(2): 171. CrossRef
Correspondence on Letter regarding “Prognosis of biopsy-confirmed MASLD: A sub-analysis of the CLIONE study” Hideki Fujii, Michihiro Iwaki, Yoshihiro Kamada Clinical and Molecular Hepatology.2024; 30(2): 281. CrossRef
In response to: Steatotic liver disease-know your enemies Michael H. Le, Linda Henry, Mindie H. Nguyen Clinical and Molecular Hepatology.2024; 30(2): 284. CrossRef
Treatment of Metabolic Disorders Using Novel DGAT2 Inhibitors: Pyrazolopyridine and Triazolopyridine Derivatives Robert B. Kargbo ACS Medicinal Chemistry Letters.2024; 15(8): 1199. CrossRef
Fatty acid composition of blood serum and erythrocyte membranes in men with steatosis and steatohepatitis with normal transaminase activity M. V. Kruchinina, M. F. Osipenko, A. A. Shestov, M. V. Parulikova Sechenov Medical Journal.2024; 15(2): 48. CrossRef
Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions Lung-Yi Mak, Ken Liu, Sakkarin Chirapongsathorn, Kuo Chao Yew, Nobuharu Tamaki, Ruveena Bhavani Rajaram, Mara Teresa Panlilio, Rashid Lui, Hye Won Lee, Jimmy Che-To Lai, Anand V. Kulkarni, Madhumita Premkumar, Cosmas Rinaldi Adithya Lesmana, Yao Chun Hsu, Nature Reviews Gastroenterology & Hepatology.2024; 21(12): 834. CrossRef
Cross-generational effects of dietary sea buckthorn on non-alcoholic fatty liver disease in offspring of obese female mice Weipeng Zhang, Yonghua Shi, Yu Wang, Xuan Liu, Jianchen Yan, Haoran Chen, Junxing Zhao Journal of Functional Foods.2024; 121: 106398. CrossRef
An analysis of the burden of liver cirrhosis: Differences between the global, China, the United States and India Keqiang Lu, Juanjuan Sui, Wenhui Yu, Yan Chen, Zhiyong Hou, Pengyan Li, Yuli Sun Liver International.2024; 44(12): 3183. CrossRef
The Predictive Value of Time‐Varying Noninvasive Scores on Long‐Term Prognosis of NAFLD in South Korea Sung Won Chung, Min Kyung Park, Xiao Zhang, Tongtong Wang, Thomas Jemielita, Gail Fernandes, Samuel S. Engel, Heejoon Jang, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim, Xingshun Qi Canadian Journal of Gastroenterology and Hepatology.2024;[Epub] CrossRef
Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi Clinical and Molecular Hepatology.2024; 30(4): 962. CrossRef
Reply to correspondence on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis” Tian-Yi Ren, Mohammed Eslam, Jian-Gao Fan Clinical and Molecular Hepatology.2024; 30(4): 1039. CrossRef
PAMK Ameliorates Non-Alcoholic Steatohepatitis and Associated Anxiety/Depression-like Behaviors Through Restoring Gut Microbiota and Metabolites in Mice Jianmei Yang, Wanyi Ou, Guiru Lin, Yuanfei Wang, Dongliang Chen, Ze Zeng, Zumin Chen, Xiaomin Lu, Aiping Wu, Chenli Lin, Yinji Liang Nutrients.2024; 16(22): 3837. CrossRef
Pathogenesis and management of metabolic dysfunction-associated
steatohepatitis-related hepatocellular carcinoma: a narrative
review Han Ah Lee The Ewha Medical Journal.2024;[Epub] CrossRef
Evolving epidemiology of non-alcoholic fatty liver disease in South Korea: incidence, prevalence, progression, and healthcare implications from 2010 to 2022 Jae Woo Park, Jeong-Ju Yoo, Dong Hyeon Lee, Young Chang, Hoongil Jo, Young Youn Cho, Sangheun Lee, Log Young Kim, Jae Young Jang The Korean Journal of Internal Medicine.2024; 39(6): 931. CrossRef
Acetaminophen protein adduct concentrations during therapeutic dosing in patients with class II-III obesity compared to non-obese and overweight patients: a prospective observational gender stratified cohort study H.A. De Baerdemaeker, P De Cock, L De Baerdemaeker Acta Anaesthesiologica Belgica.2024; 75(Supplement): 63. CrossRef
Vy H. Nguyen, Isaac Le, Audrey Ha, Richard Hieu Le, Nicholas Ajit Rouillard, Ashley Fong, Surya Gudapati, Jung Eun Park, Mayumi Maeda, Scott Barnett, Ramsey Cheung, Mindie H. Nguyen
Clin Mol Hepatol 2023;29(4):1002-1012. Published online September 11, 2023
Background/Aims Understanding of nonalcoholic fatty liver disease (NAFLD) continues to expand, but the relationship between race and ethnicity and NAFLD outside the use of cross-sectional data is lacking. Using longitudinal data, we investigated the role of race and ethnicity in adverse outcomes in NAFLD patients. Methods: Patients with NAFLD confirmed by imaging via manual chart review from any clinics at Stanford University Medical Center (1995–2021) were included. Primary study outcomes were incidence of liver events and mortality (overall and non-liver related). Results: The study included 9,340 NAFLD patients: White (44.1%), Black (2.29%), Hispanic (27.9%), and Asian (25.7%) patients. For liver events, the cumulative 5-year incidence was highest among White (19.1%) patients, lowest among Black (7.9%) patients, and similar among Asian and Hispanic patients (~15%). The 5-year and 10-year cumulative overall mortality was highest for Black patients (9.2% and 15.0%, respectively, vs. 2.5–3.5% and 4.3–7.3% in other groups) as well as for non-liver mortality. On multivariable regression analysis, compared to White patients, only Asian group was associated with lower liver-related outcomes (aHR: 0.83, P=0.027), while Black patients were at more than two times higher risk of both non-liver related (aHR: 2.35, P=0.010) and overall mortality (aHR: 2.13, P=0.022) as well as Hispanic patients (overall mortality: aHR: 1.44, P=0.022).Conclusions: Compared to White patients, Black patients with NAFLD were at the highest risk for overall and non-liver-related mortality, followed by Hispanic patients with Asian patients at the lowest risk for all adverse outcomes. Culturally sensitive and appropriate programs may be needed for more successful interventions.
Citations
Citations to this article as recorded by
Ethnic disparities in metabolic dysfunction-associated steatotic liver disease and clinical outcomes Yusuke Miyatani, Aoi Ogawa, Tomoki Sempokuya, Chuong Tran, Davis James, Todd Seto, Cecilia Shikuma, Scott K. Kuwada Frontiers in Endocrinology.2026;[Epub] CrossRef
Meta‐Analysis: Global Prevalence and Mortality of Cirrhosis in Metabolic Dysfunction‐Associated Steatotic Liver Disease Soroor Owrangi, James M. Paik, Pegah Golabi, Leyla de Avila, Ryuki Hashida, Ariana Nader, Annette Paik, Linda Henry, Zobair M. Younossi Alimentary Pharmacology & Therapeutics.2025; 61(3): 433. CrossRef
Statin use and liver-related prognosis among patients with MASLD Byungyoon Yun, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin-Ha Yoon JHEP Reports.2025; 7(4): 101313. CrossRef
Ethnic differences in metabolic and histologic features among White, Hispanic, Black and Asian patients with metabolic-associated Steatotic liver disease: A network meta-analysis Limin Lin, Jiaming Lai, Ling Luo, Junzhao Ye, Bihui Zhong Annals of Hepatology.2025; 30(2): 101780. CrossRef
Representation of Sex, Race and Ethnicity in MASH Randomised Controlled Trials: A Systematic Review and Meta‐Analysis Matheus Souza, Lubna Al‐Sharif, Ivanna Diaz, Samira Mohamad Khalil, Xiu‐He Lv, Alessandro Mantovani, Cristiane Alves Villela‐Nogueira Liver International.2025;[Epub] CrossRef
Differential Characteristics and Survival Outcomes of Patients With Cirrhosis According to Underlying Liver Aetiology Yu Shi, Nicholas Chien, Ashley Fong, Vy H. Nguyen, Surya Teja Gudapati, Angela Chau, Sally Tran, Linda Henry, Ramsey Cheung, Changqing Zhao, Minjuan Jin, Mindie H. Nguyen Alimentary Pharmacology & Therapeutics.2025; 61(10): 1622. CrossRef
Correspondence to letter to the editor 2 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study” Seogsong Jeong, Won Kim, Sang Min Park Clinical and Molecular Hepatology.2025; 31(2): e210. CrossRef
Racial and Ethnic Disparities in NAFLD: Harnessing Epigenetic and Gut Microbiota Pathways for Targeted Therapeutic Approaches Mohamed Zaiou, Olivier Joubert Biomolecules.2025; 15(5): 669. CrossRef
Young Adults With Metabolic Dysfunction–Associated Steatotic Liver Disease Have an Increased Risk of Early-Onset Cancer: A Nationwide Cohort Study Differentiating the Risk of 23 Site-Specific Cancers Joon Ho Moon, Seogsong Jeong, Heejoon Jang, Dong Hyeon Lee, Sae Kyung Joo, Bo Kyung Koo, Qiang Xia, Meng Sha, Yoosoo Chang, Won Kim Clinical Gastroenterology and Hepatology.2025; 23(13): 2540. CrossRef
Projected Trends in Metabolic Dysfunction–Associated Steatotic Liver Disease Mortality Through 2040 Xinrong Zhang, Sovann Linden, Charles R. Levesley, Xinyuan He, Zhanpeng Yang, Scott D. Barnet, Ramsey Cheung, Fanpu Ji, Mindie H. Nguyen JAMA Network Open.2025; 8(6): e2516367. CrossRef
Targeting MASLD and MASH in the US Hispanic/Latino Population Nicholas A. Cumpian, Julio A. Gutierrez, William Wu, Sammy Saab JAMA Internal Medicine.2025; 185(11): 1376. CrossRef
Comparison of diagnostic criteria for fatty liver disease in assessing cardiac dysfunction: a cross-sectional study Yun Kyung Cho, Myung Jin Kim, Eun Hee Kim, Min Jung Lee, Hyo-Jung Nam, Woo Je Lee, Hong-Kyu Kim, Chang Hee Jung Hepatology International.2025;[Epub] CrossRef
Comment on “Comparison of diagnostic criteria for fatty liver disease in assessing cardiac dysfunction: a cross-sectional study” Bin Cao, Zhenxing Deng, Ming Ouyang Hepatology International.2025;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease in Egypt: Epidemiology, risk factors and management challenges Walaa Abdelhamed, Mona Amin, Imam Waked, Mohamed El-Kassas World Journal of Gastroenterology.2025;[Epub] CrossRef
Sex and Race-Ethnic Disparities in Metabolic Dysfunction-Associated Steatotic Liver Disease: An Analysis of 40,166 Individuals Clarissa Elysia Fu, Margaret Teng, Daniel Tung, Vijay Ramadoss, Christen Ong, Benjamin Koh, Wen Hui Lim, Darren Jun Hao Tan, Jia Hong Koh, Benjamin Nah, Nicholas Syn, Nobuharu Tamaki, Mohammad Shadab Siddiqui, Karn Wijarnpreecha, George N. Ioannou, Atsush Digestive Diseases and Sciences.2024; 69(9): 3195. CrossRef
Intervening on Metabolic Dysfunction-Associated Steatotic Liver Disease in Latino/a and Black Patients with Diabetes: A Feasibility Pilot Anastasia-Stefania Alexopoulos, Susanne Danus, Alice Parish, Maren K. Olsen, Bryan C. Batch, Connie R. Thacker, Cynthia A. Moylan, Matthew J. Crowley Diabetes Therapy.2024; 15(11): 2417. CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease Is Associated with Increased Risk of Kidney Cancer: A Nationwide Study Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon, Hyung Ho Lee, Heejoo Park, Jian Lee, Youngsun Park, Byungyoon Yun, Jinsoo Chung Cancers.2024; 16(18): 3161. CrossRef
Prevalence and Characteristics of Metabolic Dysfunction-Associated Fatty Liver Disease among an Iranian Adult Population with Ethnic and Genetic Diversity: Results of the PolyIran-Liver Study Elham Jafari, Shahin Merat, Amir Anoushiravani, Amir Reza Radmard, Gholamreza Roshandel, Maryam Sharafkhah, Masoud Khoshnia, Alireza Nateghi, Abolfazl Shiravi Khuzani, Hossein Poustchi, Reza Malekzadeh Middle East Journal of Digestive Diseases.2024; 16(2): 86. CrossRef
Disparities in Heart Failure Deaths among Patients with Cirrhosis Benjamin Grobman, Arian Mansur, Christine Y. Lu Journal of Clinical Medicine.2024; 13(20): 6153. CrossRef
Racial and ethnic disparities in metabolic dysfunction-associated steatotic liver disease outcomes: A call for culturally sensitive interventions: Editorial on “Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and e Jae Hyun Bae Clinical and Molecular Hepatology.2024; 30(4): 665. CrossRef
Differences in major adverse cardiovascular events of metabolic dysfunction-associated steatotic liver disease by race and ethnicity: Letter to the editor on “Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and eth Hui-Chin Chang, Wen-Chieh Liao, Yi-Jen Fang, Shiu-Jau Chen, Shuo-Yan Gau Clinical and Molecular Hepatology.2024; 30(4): 978. CrossRef
Reply to correspondence on “Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study” Jae Hyun Bae Clinical and Molecular Hepatology.2024; 30(4): 1047. CrossRef
Correspondence to editorial on “Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study” Vy H. Nguyen, Mindie H. Nguyen Clinical and Molecular Hepatology.2024; 30(4): 1000. CrossRef
Background/Aims Chronic hepatitis B (CHB) and fatty liver (FL) often co-exist, but natural history data of this dual condition (CHB-FL) are sparse. Via a systematic review, conventional meta-analysis (MA) and individual patient-level data MA (IPDMA), we compared liver-related outcomes and mortality between CHB-FL and CHB-no FL patients.
Methods We searched 4 databases from inception to December 2021 and pooled study-level estimates using a random- effects model for conventional MA. For IPDMA, we evaluated outcomes after balancing the two study groups with inverse probability treatment weighting (IPTW) on age, sex, cirrhosis, diabetes, ALT, HBeAg, HBV DNA, and antiviral treatment.
Results We screened 2,157 articles and included 19 eligible studies (17,955 patients: 11,908 CHB-no FL; 6,047 CHB-FL) in conventional MA, which found severe heterogeneity (I2=88–95%) and no significant differences in HCC, cirrhosis, mortality, or HBsAg seroclearance incidence (P=0.27–0.93). IPDMA included 13,262 patients: 8,625 CHB-no FL and 4,637 CHB-FL patients who differed in several characteristics. The IPTW cohort included 6,955 CHB-no FL and 3,346 CHB-FL well-matched patients. CHB-FL patients (vs. CHB-no FL) had significantly lower HCC, cirrhosis, mortality and higher HBsAg seroclearance incidence (all p≤0.002), with consistent results in subgroups. CHB-FL diagnosed by liver biopsy had a higher 10-year cumulative HCC incidence than CHB-FL diagnosed with non-invasive methods (63.6% vs. 4.3%, p<0.0001).
Conclusions IPDMA data with well-matched CHB patient groups showed that FL (vs. no FL) was associated with significantly lower HCC, cirrhosis, and mortality risk and higher HBsAg seroclearance probability.
Citations
Citations to this article as recorded by
Prediction of Hepatocellular Carcinoma and Other Liver‐Related Events in Chronic Hepatitis B Patients With Metabolic Dysfunction or Metabolic Dysfunction‐Associated Steatotic Liver Disease Lesley A. Patmore, Ivana Carey, Jordan J. Feld, Willem P. Brouwer, Keyur Patel, Maria Buti, Pieter Honkoop, Douwe F. Postma, Hans Blokzijl, Özgur. M. Koc, Eva van Oorschot, Kosh Agarwal, Marc van der Valk, Faydra I. Lieveld, Mai Kilany, Matthijs Kramer, J Alimentary Pharmacology & Therapeutics.2026; 63(3): 374. CrossRef
Impact of Non‐Alcoholic Fatty Liver Disease on the HBsAg Loss of Patients With Chronic Hepatitis B Treated in Pegylated Interferon Alpha Chujing Li, Lihua Lin, Pei Zhou, Haiyi Cai, Songlian Liu, Xiaoyuan Chen, Aiqi Lu, Bo Li, Yaping Wang, Chuanghua Luo, Jianping Li, Yujuan Guan, Zhiwei Xie Journal of Viral Hepatitis.2026;[Epub] CrossRef
Association between deletions in the preS1/2 region of the hepatitis B virus genome and persistently abnormal ALT levels in patients with chronic hepatitis B treated with nucleos(t)ide analogs Yurina Sato, Kotaro Doi, Jun Inoue, Masashi Ninomiya, Mio Tsuruoka, Kosuke Sato, Masazumi Onuki, Satoko Sawahashi, Keishi Ouchi, Kengo Watanabe, Hirofumi Niitsuma, Atsushi Masamune Archives of Virology.2026;[Epub] CrossRef
Risk stratification of metabolic dysfunction-associated steatotic liver disease: The KASL pathway: Editorial on “Risk stratification by noninvasive tests in patients with metabolic dysfunction-associated steatotic liver disease” May Xuan Goh, Xin En Goh, Jarell Jie-Rae Tan, Vincent L Chen, Yu Jun Wong Clinical and Molecular Hepatology.2026; 32(1): 429. CrossRef
Metabolic health in antiviral era of chronic hepatitis B: Editorial on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues” Shang-Chin Huang, Jia-Horng Kao Clinical and Molecular Hepatology.2026; 32(1): 423. CrossRef
Diagnostic value of transient elastography in assessing the degree of liver fibrosis in chronic hepatitis B patients with low alanine aminotransferase levels and concomitant hepatic steatosis Aili Wang, Qingqing Wang, Huaie Liu Saudi Journal of Gastroenterology.2026;[Epub] CrossRef
Type 2 diabetes as a key metabolic risk factor for adverse outcomes in nucleos(t)ide analogue-treated chronic hepatitis B: Editorial on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)id Heejoon Jang, Won Kim Clinical and Molecular Hepatology.2026; 32(1): 426. CrossRef
Correspondence to editorial 2 on “Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues” Rui Huang, Mindie H. Nguyen Clinical and Molecular Hepatology.2026; 32(1): e85. CrossRef
Obesity management for the hepatologist—What to do, how to do it and why? Kymberly D. Watt, Sonali Paul, Mohammad Qasim Khan, Mohammad Siddiqui, Jenny Lam, Tayyab S. Diwan, Michael Camilleri Hepatology.2025; 81(5): 1607. CrossRef
Pre-Existing and New-Onset Metabolic Dysfunctions Increase Cirrhosis and Its Complication Risks in Chronic Hepatitis B Shang-Chin Huang, Tung-Hung Su, Tai-Chung Tseng, Sih-Han Liao, Shih-Jer Hsu, Chun-Ming Hong, Ting-Yuan Lan, Chen-Hua Liu, Hung-Chih Yang, Chun-Jen Liu, Jia-Horng Kao American Journal of Gastroenterology.2025; 120(2): 401. CrossRef
Outcomes of radiofrequency ablation for hepatocellular carcinoma with concurrent steatotic liver disease Feng‐Pai Tsai, Tung‐Hung Su, Shang‐Chin Huang, Tai‐Chung Tseng, Shih‐Jer Hsu, Sih‐Han Liao, Chun‐Ming Hong, Chen‐Hua Liu, Hung‐Chih Yang, Chun‐Jen Liu, Pei‐Jer Chen, Jia‐Horng Kao Cancer.2025;[Epub] CrossRef
Impact of age at HBsAg seroclearance on hepatic outcomes and life expectancy in men with chronic HBV infection based on multi-state modeling of the natural history Wen-Jie Liu, Wan-Jung Wu, Chih-Lin Lin, Chun-Jen Liu, Yi-Wen Huang, Jui-Ting Hu, Ming-Whei Yu Journal of Gastroenterology.2025; 60(1): 107. CrossRef
All-cause and cause-specific mortality in patients with chronic hepatitis B and concurrent steatotic liver disease Shang-Chin Huang, Tung-Hung Su, Tai-Chung Tseng, Shih-Jer Hsu, Chun-Ming Hong, Ting-Yuan Lan, Chen-Hua Liu, Hung-Chih Yang, Chun-Jen Liu, Jia-Horng Kao Journal of Hepatology.2025; 83(1): 43. CrossRef
The 2024 updated WHO guidelines for the prevention and management of chronic hepatitis B: Main changes and potential implications for the next major liver society clinical practice guidelines Grace Lai-Hung Wong, Maud Lemoine Journal of Hepatology.2025; 82(5): 918. CrossRef
The Asian Pacific association for the study of the liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease Mohammed Eslam, Jian-Gao Fan, Ming-Lung Yu, Vincent Wai-Sun Wong, Ian Homer Cua, Chun-Jen Liu, Tawesak Tanwandee, Rino Gani, Wai-Kay Seto, Shahinul Alam, Dan Yock Young, Saeed Hamid, Ming-Hua Zheng, Takumi Kawaguchi, Wah-Kheong Chan, Diana Payawal, Soek-S Hepatology International.2025; 19(2): 261. CrossRef
SLC22A1 Resists Hepatitis B Virus by Activating the JAK/STAT Pathway and Predicts the Effect of Pegylated Interferon α–Based Therapy on Chronic Hepatitis B Huiying Yu, Bin Li, Huili Guo, Lin Li, Xiaoquan Liu, Lili Wu, Na Gao, Qiyi Zhao, Xiuqing Pang, Zhiliang Gao The Journal of Infectious Diseases.2025; 232(2): 474. CrossRef
Impact of hepatic steatosis on mortality, hepatocellular carcinoma, end-stage liver disease and HBsAg seroclearance in chronic hepatitis B: a United States cohort study George A. Yendewa, Abbinaya Elangovan, Temitope Olasehinde, Frank Mulindwa, Mackenzie G. Cater, Robert A. Salata, Jeffrey M. Jacobson Frontiers in Immunology.2025;[Epub] CrossRef
Cohort Profile: Taizhou Study of Liver Diseases (T-SOLID) Zhenqiu Liu, Yanfeng Jiang, Chen Suo, Huangbo Yuan, Ziyu Yuan, Tiejun Zhang, Li Jin, Xingdong Chen International Journal of Epidemiology.2025;[Epub] CrossRef
Unraveling Demographic Patterns in Hepatitis B Clinical and Laboratory Profiles: Insights From a Ghanaian Cohort: A Retrospective Study Napoleon Bellua Sam, Saeed Folorunsho Majeed, Adams Dramani Health Science Reports.2025;[Epub] CrossRef
EASL Clinical Practice Guidelines on the management of hepatitis B virus infection Markus Cornberg, Lisa Sandmann, Jerzy Jaroszewicz, Patrick Kennedy, Pietro Lampertico, Maud Lemoine, Sabela Lens, Barbara Testoni, Grace Lai-Hung Wong, Francesco Paolo Russo Journal of Hepatology.2025; 83(2): 502. CrossRef
Increasing Treatment Uptake for Chronic Hepatitis B in South America: A Comparative Analysis of Country‐Specific and WHO 2024 Guidelines Manuel Mendizabal, Constanza D. Sabate, Esteban González Ballerga, Fernando Gruz, Ezequiel Ridruejo, Alejandro Soza, Jaime Poniachik, Grace Vergara, Victoria Mainardi, Gabriel Mezzano, Fernando Bessone, Margarita Anders, Mario G. Pessoa, Fernando Cairo, D Journal of Viral Hepatitis.2025;[Epub] CrossRef
Differential HCC risk among HBV indeterminate types at baseline and by phase transition Rui Huang, Huy N Trinh, Satoshi Yasuda, Angela Chau, Mayumi Maeda, Ai-Thien Do, Daniel Q Huang, Takanori Ito, Takashi Honda, Masatoshi Ishigami, Ritsuzo Kozuka, Carmen Monica Preda, Cheng-Hao Tseng, Sebastián Marciano, Pei-Chien Tsai, Dong Hyun Lee, Chris Gut.2025; 74(11): 1873. CrossRef
Impact of Metabolic Dysfunction-Associated Fatty Liver Disease of Varying Severity on Antiviral Treatment Outcomes and Clinical Prognosis in Patients with Chronic Hepatitis B: A Systematic Review and Meta-analysis Qianqian Zhu, Chengde Su, Mingdan Li, Yali Xu, Qian Liu, Ying Zhang, Xinyi Zhang, Qiuxiang Li, Huajun Wang, Yawen Luo, Ping Yang Infectious Diseases and Therapy.2025; 14(8): 1599. CrossRef
Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues Rui Huang, Dae Won Jun, Hidenori Toyoda, Yao-Chun Hsu, Huy Trinh, Akito Nozaki, Toru Ishikawa, Tsunamasa Watanabe, Haruki Uojima, Daniel Q. Huang, Takashi Honda, Yasuhito Tanaka, Philip Vutien, Sebastián Marciano, Hiroshi Abe, Masaru Enomoto, Masanori Ats Clinical and Molecular Hepatology.2025; 31(3): 1003. CrossRef
Type 2 diabetes mellitus as an independent predictor of significant fibrosis in treatment-naïve chronic hepatitis B patients with concurrent hepatic steatosis Jie Li, Liang Xu, Fajuan Rui, Sally Tran, Pei-Chien Tsai, Youwen Tan, Hidenori Toyoda, Qing-Lei Zeng, Huy Trinh, Yao-Chun Hsu, Tsunamasa Watanabe, Hiroshi Abe, Hiroyuki Motoyama, Yoko Yoshimaru, Takanori Suzuki, Taeang Arai, Masanori Atsukawa, Phillip Vut Hepatology.2025;[Epub] CrossRef
Impact of metabolic dysfunction on treatment responses to nucleos(t)ide analogues in chronic hepatitis B: a retrospective multi-center REAL-B cohort study Rui Huang, Dae Won Jun, Hidenori Toyoda, Yao-Chun Hsu, Huy Trinh, Akito Nozaki, Toru Ishikawa, Tsunamasa Watanabe, Haruki Uojima, Daniel Q. Huang, Takashi Honda, Yasuhito Tanaka, Philip Vutien, Sebastián Marciano, Hiroshi Abe, Masaru Enomoto, Masanori Ats eClinicalMedicine.2025; 87: 103407. CrossRef
Editorial: Advancing HCC Surveillance in Hepatitis B With Biomarker‐Based Strategy Yu Jun Wong Alimentary Pharmacology & Therapeutics.2025;[Epub] CrossRef
Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis Frances Sze Kei Sun, Jeffrey Sum Lung Wong, Lung-Yi Mak, Carmen Chak-Lui Wong, Valerie Chew, Bryan Cho Wing Li, Roland Leung, Tan To Cheung, Thomas Yau Liver Cancer.2025; : 1. CrossRef
Impact of fatty liver disease on hepatic function and fibrosis progression in chronic hepatitis B patients: a narrative review Rushi V. Mukkawar, Nishant Rathod, Rajvardhan Patil, Sunil Kumar, Sourya Acharya International Journal of Nutrition, Pharmacology, Neurological Diseases.2025; 15(4): 368. CrossRef
Association Between SGLT2 Inhibitor Use and Reduced Risk of Liver-Related Events, Including Hepatocellular Carcinoma, in Diabetic Patients with Viral Hepatitis: A Nationwide Cohort Study Seong Hee Kang, Jimi Choi, Hyung Joon Yim, Young Kul Jung, Sun Young Yim, Young-Sun Lee, Yeon Seok Seo, Ji Hoon Kim, Jong Eun Yeon, Kwan Soo Byun Cancers.2025; 18(1): 120. CrossRef
Chronic Hepatitis B and Steatotic Liver Disease: A Blessing in Disguise? Xiaoming Xu, Mindie H. Nguyen, Jie Li Clinical Gastroenterology and Hepatology.2024; 22(9): 1956. CrossRef
Liver function indicators and risk of hepatocellular carcinoma: a bidirectional mendelian randomization study Shanshan Qin, Jing Wang, Haiqing Yuan, Jingzhen He, Shoujing Luan, Yan Deng Frontiers in Genetics.2024;[Epub] CrossRef
The co-existence of NAFLD and CHB is associated with suboptimal viral and biochemical response to CHB antiviral therapy: a systematic review and meta-analysis Georgia Zeng, Benjamin R. Holmes, Saleh A. Alqahtani, Upkar S. Gill, Patrick T. F. Kennedy Frontiers in Gastroenterology.2024;[Epub] CrossRef
Exploring the Multifaceted Landscape of MASLD: A Comprehensive Synthesis of Recent Studies, from Pathophysiology to Organoids and Beyond Allison Soto, Colby Spongberg, Alessandro Martinino, Francesco Giovinazzo Biomedicines.2024; 12(2): 397. CrossRef
Impact of chronic hepatitis B and concurrent steatosis on the risk of hepatocellular carcinoma Ibrahim Ayada, Jiajing Li, Willem Pieter Brouwer, Robert J. de Knegt, Qiuwei Pan Hepatology International.2024; 18(3): 1053. CrossRef
Mortality in patients with chronic hepatitis B treated with tenofovir or entecavir: A multinational study Tyng‐Yuan Jang, Po‐Cheng Liang, Dae Won Jun, Jang Han Jung, Hidenori Toyoda, Chih‐Wen Wang, Man‐Fung Yuen, Ka Shing Cheung, Satoshi Yasuda, Sung Eun Kim, Eileen L Yoon, Jihyun An, Masaru Enomoto, Ritsuzo Kozuka, Makoto Chuma, Akito Nozaki, Toru Ishikawa, Journal of Gastroenterology and Hepatology.2024; 39(6): 1190. CrossRef
Impact of metabolic disorders on chronic hepatitis B Shang-Chin Huang, Chun-Jen Liu, Jia-Horng Kao Clinical Liver Disease.2024;[Epub] CrossRef
Antiviral therapy response in patients with chronic hepatitis B and fatty liver: A systematic review and meta‐analysis Fajuan Rui, Elizabeth Garcia, Xinyu Hu, Wenjing Ni, Qi Xue, Yayun Xu, Xiaoming Xu, Junping Shi, Mindie H. Nguyen, Ramsey C. Cheung, Jie Li Journal of Viral Hepatitis.2024; 31(7): 372. CrossRef
Inpatient Cost Burdens of Treating Chronic Hepatitis B in US Hospitals: A Weighted Analysis of a National Database David Uihwan Lee, Kuntal Bhowmick, Sindhura Kolachana, Kimberly Schuster, Aneesh Bahadur, Ashton Harmacinski, Sophie Schellhammer, Gregory Hongyuan Fan, Ki Jung Lee, Catherine Sun, Hannah Chou, Zurabi Lominadze Digestive Diseases and Sciences.2024; 69(7): 2401. CrossRef
Hepatocellular carcinoma surveillance after HBsAg seroclearance Jimmy Che-To Lai, Vicki Wing-Ki Hui, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip Exploration of Digestive Diseases.2024; : 175. CrossRef
Liver health in hemophilia in the era of gene therapy Yesim Dargaud, Massimo Levrero, François Bailly, Anne Lienhart, Fabien Zoulim Thrombosis Research.2024; 240: 109064. CrossRef
Global epidemiology, natural history, maternal-to-child transmission, and treatment with DAA of pregnant women with HCV: a systematic review and meta-analysis Joo Wei Ethan Quek, Jing Hong Loo, En Qi Lim, Ambrose Hon-Lam Chung, Abu Bakar Bin Othman, Jarell Jie-Rae Tan, Scott Barnett, Mindie H. Nguyen, Yu Jun Wong eClinicalMedicine.2024; 74: 102727. CrossRef
Dual-etiology MAFLD: the interactions between viral hepatitis B, viral hepatitis C, alcohol, and MAFLD Chun-Jen Liu, Wai Kay Seto, Ming-Lung Yu Hepatology International.2024; 18(S2): 897. CrossRef
Canadian Association for the Study of the Liver Single Topic Conference on Hepatitis B Virus: ‘Progress toward hepatitis B elimination in Canada’ Julian Hercun, Golasa Samadi Kochaksaraei, Simmone D'souza, Rachel Talavlikar, Jennifer Van Gennip, Carla Osiowy, Carla S Coffin, Harley Crowshoe Canadian Liver Journal.2024; 7(3): 385. CrossRef
Chronic hepatitis B and metabolic dysfunction-associated steatotic liver disease: Metabolic risk factors are key drivers of hepatocellular carcinoma Gupse Adali, Huseyin Aykut, Nermin Mutlu Bilgic, Yusuf Yilmaz Heliyon.2024; 10(18): e37990. CrossRef
Influence of nonalcoholic fatty liver disease on the therapeutic effect of nucleoside (acid) analogs for hepatitis B virus Hua-Dong Li, Ya-Nan Liu, Shuang Wu, Xu-Feng Quan, Xiao-Yan Wang, Tian-Dan Xiang, Shu-Meng Li, Ling Xu, Tong Wang, Hua Wang, Xin Zheng World Journal of Hepatology.2024; 16(12): 1395. CrossRef
Revolutionizing the understanding of liver disease: Metabolism, function and future Arnulfo E Morales-Galicia, Mariana M Ramírez-Mejía, Guadalupe Ponciano-Rodriguez, Nahum Méndez-Sánchez World Journal of Hepatology.2024; 16(12): 1365. CrossRef
The latest evidence on the impact of fatty liver on liver-related outcomes and mortality in chronic hepatitis B Xianhua Mao, Lung Yi Mak, Wai-Kay Seto Clinical and Molecular Hepatology.2023; 29(3): 690. CrossRef
Survival of Patients with Hepatitis B-Related Hepatocellular Carcinoma with Concomitant Metabolic Associated Fatty Liver Disease Yajing You, Tao Yang, Shuhang Wei, Zongxin Liu, Chenxi Liu, Zijian Shen, Yinuo Yang, Yuemin Feng, Ping Yao, Qiang Zhu Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 2283. CrossRef
From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials Ming-Lun Yeh, Ming-Lung Yu Clinical and Molecular Hepatology.2023; 29(4): 969. CrossRef
Persistent steatosis correlates with decreased fibrosis regression during anti‐HBV treatment in patients with chronic HBV infection Mengyang Zhang, Shuyan Chen, Xiaoning Wu, Jialing Zhou, Tailing Wang, Hui Liu, Xinyan Zhao, Bingqiong Wang, Xinyu Zhao, Yuanyuan Kong, Gwyneth Shook Ting Soon, Xiaojuan Ou, Jidong Jia, Wei Chen, Yameng Sun, Hong You Journal of Medical Virology.2023;[Epub] CrossRef
Waiting for the changes after the adoption of steatotic liver disease Eileen L. Yoon, Dae Won Jun Clinical and Molecular Hepatology.2023; 29(4): 844. CrossRef
Background/Aims Due to increases in obesity and type 2 diabetes, the prevalence of nonalcoholic fatty liver disease (NAFLD) has also been increasing. Current forecast models may not include non-obese NAFLD. Here, we used the Bayesian approach to forecast the prevalence of NAFLD through the year 2040.
Methods Prevalence data from 245 articles involving 2,699,627 persons were used with a hierarchical Bayesian approach to forecast the prevalence of NAFLD through 2040. Subgroup analyses were performed for age, gender, presence of metabolic syndrome, region, and smoking status. Sensitivity analysis was conducted for clinical setting and study quality.
Results The forecasted 2040 prevalence was 55.7%, a three-fold increase since 1990 and a 43.2% increase from the 2020 prevalence of 38.9%. The estimated average yearly increase since 2020 was 2.16%. For those aged <50 years and ≥50 years, the 2040 prevalence were not significantly different (56.7% vs. 61.5%, P=0.52). There was a significant difference in 2040 prevalence by sex (males: 60% vs. 50%) but the trend was steeper for females (annual percentage change: 2.5% vs. 1.5%, P=0.025). There was no difference in trends overtime by region (P=0.48). The increase rate was significantly higher in those without metabolic syndrome (3.8% vs. 0.84%, P=0.003) and smokers (1.4% vs. 1.1%, P=0.011). There was no difference by clinical/community setting (P=0.491) or study quality (P=0.85).
Conclusion By 2040, over half the adult population is forecasted to have NAFLD. The largest increases are expected to occur in women, smokers, and those without metabolic syndrome. Intensified efforts are needed to raise awareness of NAFLD and to determine long-term solutions addressing the driving factors of the disease.
Citations
Citations to this article as recorded by
Optimized motion‐insensitive PDFF mapping of the liver Jiayi Tang, Daiki Tamada, Raphael do Vale Souza, Aaron Faacks, Jitka Starekova, Julius F. Heidenreich, Lukas Müller, Garrett C. Fullerton, Collin J. Buelo, Jeff Kammerman, Jean H. Brittain, Scott B. Reeder, Diego Hernando Magnetic Resonance in Medicine.2026; 95(1): 249. CrossRef
Proanthocyanidins from Iris lactea Pall. var. chinensis (Fisch.) Koidz alleviate non-alcoholic fatty liver disease by regulating lipid metabolism via AMPK/SREBP-1c signalling pathway Fangfang Tie, Lichengcheng Ren, Yidan Gao, Yun Wu, Qi Dong, Honglun Wang, Na Hu Journal of Ethnopharmacology.2026; 356: 120784. CrossRef
Impact of SGLT2i and GLP-1RA on liver-related events in patients with MASLD and type 2 diabetes: A network meta-analysis Lu Li, Xianhua Mao, Chi Ho Lee, David Tak Wai Lui, Rex Wan-Hin Hui, Lung-Yi Mak, Man-Fung Yuen, Ka Shing Cheung, Wai-Kay Seto JHEP Reports.2026; 8(1): 101661. CrossRef
Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Facts and Hopes Luigi E. Adinolfi, Aldo Marrone, Antonio Izzi, Antonio Craxì Journal of Clinical and Experimental Hepatology.2026; 16(1): 103411. CrossRef
Charge-based supramolecular peptide nanocomplexes for oral delivery via transporter-driven endocytosis So-Hyeon Park, Gaeun Ma, Seong Jin Park, Seong-Bin Yang, Minho Seo, Jun-Hyuck Lee, Seho Kweon, Jooho Park Biomaterials.2026; 329: 123903. CrossRef
Salty taste preference, genetic susceptibility, and risk of metabolic dysfunction-associated steatotic liver disease: insights from three prospective cohorts Shunming Zhang, Yan Yan, Yeqing Gu, Hongmei Wu, Qing Zhang, Li Liu, Yan Borné, Lu Qi, Tao Huang, Yu-Ming Chen, Kaijun Niu, Le Ma, the China Cohort Consortium Food & Function.2026;[Epub] CrossRef
Walking the VLDL tightrope in cardiometabolic diseases Mindy Kim, Ze Zheng Trends in Endocrinology & Metabolism.2025; 36(3): 278. CrossRef
Evolving Global Etiology of Hepatocellular Carcinoma (HCC): Insights and Trends for 2024 Abraham Koshy Journal of Clinical and Experimental Hepatology.2025; 15(1): 102406. CrossRef
Appendicular skeletal muscle mass is associated with metabolic dysfunction-associated steatotic liver disease severity in young men: a cross-sectional and longitudinal study Jaejun Lee, Jinson So, Chang In Han, Hyun Yang, Pil Soo Sung, Si Hyun Bae, Do Seon Song Hepatology International.2025; 19(1): 181. CrossRef
Statin Therapy is Associated With Lower Risk of Mortality Among Liver Transplant Candidates With Metabolic Dysfunction-associated Steatohepatitis Katherine M. Cooper, Ami K. Patel, Christopher A. Zammitti, Ellen Murchie, Alessandro Colletta, Deepika Devuni Journal of Clinical and Experimental Hepatology.2025; 15(2): 102427. CrossRef
The Changing Demographics and Epidemiology of Hepatocellular Carcinoma Rushabh Gujarathi, Jeremy A. Klein, Chih-Yi Liao, Anjana Pillai Clinics in Liver Disease.2025; 29(1): 1. CrossRef
Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD) Santiago Iturbe-Rey, Claudia Maccali, Marco Arrese, Patricia Aspichueta, Claudia P. Oliveira, Rui E. Castro, Ainhoa Lapitz, Laura Izquierdo-Sanchez, Luis Bujanda, Maria J. Perugorria, Jesus M. Banales, Pedro M. Rodrigues Atherosclerosis.2025; 400: 119053. CrossRef
The impact of resistance training in patients diagnosed with metabolic dysfunction-associated steatotic liver disease: a systematic review Daniele Gorski Medeiros, Luis Fernando Ferreira, Jessica da Silva Lamp, Luis Henrique Telles da Rosa European Journal of Gastroenterology & Hepatology.2025; 37(2): 129. CrossRef
Meta‐Analysis: Global Prevalence and Mortality of Cirrhosis in Metabolic Dysfunction‐Associated Steatotic Liver Disease Soroor Owrangi, James M. Paik, Pegah Golabi, Leyla de Avila, Ryuki Hashida, Ariana Nader, Annette Paik, Linda Henry, Zobair M. Younossi Alimentary Pharmacology & Therapeutics.2025; 61(3): 433. CrossRef
Interdisciplinary perspectives on the co-management of metabolic dysfunction-associated steatotic liver disease and coronary artery disease Jacob J Gries, Jeffrey V Lazarus, Paul N Brennan, Mohammad S Siddiqui, Giovanni Targher, Chim C Lang, Salim S Virani, Carl J Lavie, Scott Isaacs, Juan Pablo Arab, Kenneth Cusi, Chayakrit Krittanawong The Lancet Gastroenterology & Hepatology.2025; 10(1): 82. CrossRef
Cardiovascular-Liver-Metabolic Health: Recommendations in Screening, Diagnosis, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Cardiovascular Disease via Modified Delphi Approach Nicholas W.S. Chew, Anurag Mehta, Rachel Sze Jen Goh, Audrey Zhang, Yiming Chen, Bryan Chong, Han Shi Jocelyn Chew, Asim Shabbir, Adrian Brown, Georgios K. Dimitriadis, Daniel Q. Huang, Roger Foo, Carel W. le Roux, Gemma A. Figtree, Marat Fudim, Ambarish Circulation.2025; 151(1): 98. CrossRef
The evolving role of liver biopsy: Current applications and future prospects Purva Gopal, Xiaobang Hu, Marie E. Robert, Xuchen Zhang Hepatology Communications.2025;[Epub] CrossRef
Associations of the Intake of Individual and Multiple Flavonoids with Metabolic Dysfunction Associated Steatotic Liver Disease in the United States Chen Wang, Mengchu Li, Jiali Zhang, Hongguang Li, Yue Li, Siyu Huang, Huilian Zhu, Zhaoyan Liu Nutrients.2025; 17(2): 205. CrossRef
Performance of Noninvasive Indices for Discrimination of Metabolic Dysfunction-Associated Steatotic Liver Disease in Young Adults Jaejun Lee, Chang In Han, Dong Yeup Lee, Pil Soo Sung, Si Hyun Bae, Hyun Yang Gut and Liver.2025; 19(1): 116. CrossRef
Comparison of Referral Rates and Costs Using Fibrosis-4 and Enhanced Liver Fibrosis (ELF) Testing Strategies for Initial Evaluation of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in a Veteran Population Samrat Yeramaneni, Stephanie T Chang, Ramsey C Cheung, Donald B Chalfin, Kinpritma Sangha, H Roma Levy, Artem T Boltyenkov The Journal of Applied Laboratory Medicine.2025; 10(3): 593. CrossRef
Meta‐Analysis of Placebo‐Treated Patients: Dropout Rates From Treatment in MASH Randomised Controlled Trials Matheus Souza, Marcio J. M. Amaral, Luan C. V. Lima, Cristiane Alves Villela‐Nogueira Alimentary Pharmacology & Therapeutics.2025; 61(5): 776. CrossRef
PBCS-ConvNeXt: Convolutional Network-Based Automatic Diagnosis of Non-alcoholic Fatty Liver in Abdominal Ultrasound Images Shang-Yu Chiang, You-Wei Wang, Pei-Yuan Su, Yuan-Yen Chang, Hsu-Heng Yen, Ruey-Feng Chang Journal of Imaging Informatics in Medicine.2025; 38(5): 2878. CrossRef
A complement to epigenetics in metabolic dysfunction-associated steatotic liver disease: Editorial on “DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease” Johanna K. DiStefano, Glenn S. Gerhard Clinical and Molecular Hepatology.2025; 31(1): 297. CrossRef
Association of prebiotic/probiotic intake with MASLD: evidence from NHANES and randomized controlled trials in the context of prediction, prevention, and a personalized medicine framework Senlin Wang, Ruimin Zhang, Peisen Guo, Huawu Yang, Yanjun Liu, Hongmei Zhu EPMA Journal.2025; 16(1): 183. CrossRef
Prevention of liver cancer in the era of next-generation antivirals and obesity epidemic Hiroyuki Suzuki, Naoto Fujiwara, Amit G. Singal, Thomas F. Baumert, Raymond T. Chung, Takumi Kawaguchi, Yujin Hoshida Hepatology.2025;[Epub] CrossRef
Insights into the results of Resmetirom trials: Can a thyroid hormone receptor agonist be the holy grail of MASH therapy? Konstantinos Arvanitakis, Theocharis Koufakis, Evangelos Cholongitas, Sven Francque, Georgios Germanidis Pharmacology & Therapeutics.2025; 268: 108811. CrossRef
Association between the Fatty Liver Index, Metabolic Dysfunction-Associated Steatotic Liver Disease, and the Risk of Kidney Stones Fan Zhang, Wenjian Li Kidney and Blood Pressure Research.2025; 50(1): 115. CrossRef
Psychosocial risks in metabolic dysfunction-associated steatotic liver disease Hanne Åström, Christine Takami Lageborn, Hannes Hagström Expert Review of Gastroenterology & Hepatology.2025; 19(3): 273. CrossRef
Glucagon like peptide-1 receptor agonists as a promising therapeutic option of metabolic dysfunction associated steatotic liver disease and obesity: hitting two targets with one shot Eda Kaya, Wing-Kin Syn, Paul Manka Current Opinion in Gastroenterology.2025; 41(3): 104. CrossRef
Metabolic dysfunction-associated steatotic liver disease (MASLD): a systemic disease with a variable natural history and challenging management Luigi Elio Adinolfi, Aldo Marrone, Luca Rinaldi, Riccardo Nevola, Antonio Izzi, Ferdinando Carlo Sasso Exploration of Medicine.2025;[Epub] CrossRef
Analyzing MASLD interventional clinical trial registration based on the ClinicalTrials.gov database Hui Du, Jihan Huang, Youhua Wang, Chunyan Wang, Yiqun Wang, Luming Hou, Yali Li, Ying Li, Qianmin Su BMC Gastroenterology.2025;[Epub] CrossRef
The relationship between the ratio of non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol (NHHR) and both MASLD and advanced liver fibrosis: evidence from NHANES 2017–2020 Juyi Li, Chunjia Kou, Yuwei Chai, Yuchen Li, Xue Liu, Li Zhang, Haiqing Zhang Frontiers in Nutrition.2025;[Epub] CrossRef
Therapeutic Potential of GLP-1 Receptor Agonists in Metabolic Associated Steatotic Liver Disease Klaudia Nowak, Krzysztof Łupina, Anna Romac, Aleksandra Kalisz, Łucja Ilkiewicz, Jakub Janczura Annals of Pharmacotherapy.2025; 59(10): 928. CrossRef
miR-125b-5p regulates FFA-induced hepatic steatosis in L02 cells by targeting estrogen-related receptor alpha Fen Gao, Yanhua Ma, Chun Yu, Qianchen Duan Gene.2025; 959: 149419. CrossRef
Epidemiology of metabolic dysfunction-associated steatotic liver disease Zobair M. Younossi, Markos Kalligeros, Linda Henry Clinical and Molecular Hepatology.2025; 31(Suppl): S32. CrossRef
Unraveling the molecular mechanisms of Fufangduzhong formula in alleviating high-fat diet-induced non-alcoholic fatty liver disease in mice Yu Mou, Yao Tang, Xiuyan Zheng, Xiang Liu, Xuemei Wu, Hongji Wang, Jie Zeng, Qing Rao, Yaacov Ben-David, Yanmei Li, Lei Huang Frontiers in Pharmacology.2025;[Epub] CrossRef
Steatotic Liver Disease in Younger Adults is Associated With Altered Gut Microbiology Yasmina Tashkent, Jocelyn M. Choo, Alyson Richard, Zhengyi Wang, Luis Calzadilla‐Bertot, Egi Vasil, Sophie Miller, Steven L. Taylor, Kerry L. Ivey, Richard Woodman, Brendan Adler, Oyekoya T. Ayonrinde, John K. Olynyk, Lawrence J. Beilin, Trevor A. Mori, A Liver International.2025;[Epub] CrossRef
Low HDL cholesterol levels in women and hypertriglyceridemia in men: predictors of MASLD onset in individuals without steatosis Tsubasa Tsutsumi, Takumi Kawaguchi, Hideki Fujii, Yoshihiro Kamada, Yuichiro Suzuki, Koji Sawada, Miwa Tatsuta, Tatsuji Maeshiro, Hiroshi Tobita, Takemi Akahane, Chitomi Hasebe, Miwa Kawanaka, Takaomi Kessoku, Yuichiro Eguchi, Hayashi Syokita, Atsushi Nak Journal of Gastroenterology.2025; 60(7): 891. CrossRef
The emerging role of E3 ubiquitin ligases and deubiquitinases in metabolic dysfunction-associated steatotic liver disease Yu Zhang, Jiahui Yang, Jiali Min, Shan Huang, Yuchen Li, Shanshan Liu Journal of Translational Medicine.2025;[Epub] CrossRef
MASLD: Prevalence, Mechanisms, and Sex-Based Therapies in Postmenopausal Women Ilaria Milani, Marianna Chinucci, Frida Leonetti, Danila Capoccia Biomedicines.2025; 13(4): 855. CrossRef
C-C motif chemokines ligand 7 contributes to metabolic dysfunction-associated steatotic liver disease by enabling redox-sensitive induction of hypermethylated in cancer 1 Xinyue Sun, Jinge Wu, Huiqian Lv, Ben Wang, Xuelian Chen, Wenjing Ren, Xiulian Miao, Yan Guo, Xiaocen Kong, Huihui Xu, Zeqing Bao, Yong Xu, Zilong Li Metabolism.2025; 168: 156242. CrossRef
Neutrophils in MASLD and MASH Sanjeeb Shrestha, Jae-Han Jeon, Chang-Won Hong BMB Reports.2025; 58(3): 116. CrossRef
ROS Signaling Controls Lipid Accumulation in HepG2 Cells Driven by Doxorubicin-Induced Senescence Chawon Yun, Seung Jun Noh, Hamed Kazemi Zahrani, Sou Hyun Kim, Young-Suk Jung Drug Targets and Therapeutics.2025; 4(1): 1. CrossRef
Construction and evaluation of a diagnostic model for metabolic dysfunction-associated steatotic liver disease based on advanced glycation end products and their receptors Xiao Cao, Xiaohua Xiao, Peipei Jiang, Nian Fu Frontiers in Medicine.2025;[Epub] CrossRef
Clinical Insights on Resmetirom Eda Kaya, Yusuf Yilmaz, Naim Alkhouri Journal of Clinical Gastroenterology.2025; 59(5): 412. CrossRef
Ernährung und körperliches Training bei Lebererkrankungen Thomas-Matthias Scherzer, Bettina Knabl, Benedikt Mehl Journal für Gastroenterologische und Hepatologische Erkrankungen.2025; 23(1): 12. CrossRef
Are glyphosate or glyphosate-based herbicides linked to metabolic dysfunction-associated steatotic liver disease (MASLD)? The weight of current evidence Luana Riechelmann-Casarin, Leticia Cardoso Valente, Rosemari Otton, Luís Fernando Barbisan, Guilherme Ribeiro Romualdo Environmental Toxicology and Pharmacology.2025; 116: 104705. CrossRef
Sex differences in the mediation of the MASLD - Depression association by fat distribution in U.S. adults Changhuai He, Liuxin Zhou, Tianming Gao, Runmin Cao, Chuanqi Cai, Guoqing Jiang Acta Psychologica.2025; 256: 105041. CrossRef
Association of biological aging and the prevalence of nonalcoholic fatty liver disease: a population-based study Gang Liu, Qingsong Mao, Xinling Tian, Chenwei Zhang, Yukai Zhang, Jiarong He, Yuzhe Kong BMC Gastroenterology.2025;[Epub] CrossRef
Association Between Uric Acid to HDL-C Ratio and Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetes Mellitus: A Cross-Sectional Study Xiangyun Zhu, Han Yin, Jing Han, Xiaoyan Zhang, Qing Han, Weixia Sun, Yijun Liu, Wenxuan Tao, Xinliang Liu, Guofeng Wang, Ling Li Diabetes, Metabolic Syndrome and Obesity.2025; Volume 18: 1459. CrossRef
Association of PNPLA3 Genetic Polymorphism with Non-Alcoholic Fatty Liver Disease in Sikkim: A Pilot Study Vaishnavi Singh, Arundhati Bag, Bidita Khandelwal, Debarghya Sutradhar National Academy Science Letters.2025;[Epub] CrossRef
Increased Mortality Among Lean Versus Non‐Lean Adults With MASLD: A Multicenter Study Leith Ghani, Majd B. Aboona, Claire S. Faulkner, Pooja Rangan, Moises Nevah Rubin, Ma Ai Thanda Han, Michael B. Fallon, Vincent L. Chen, Karn Wijarnpreecha Journal of Gastroenterology and Hepatology.2025; 40(8): 1919. CrossRef
A potential herbal component for the future treatment of fatty liver disease: Geniposide from gardenia Qinyao Zhang, Ziyan Li, Lina Wang Frontiers in Pharmacology.2025;[Epub] CrossRef
In vitro antioxidant effects and in vivo hepatoprotective effects of Osbeckia octandra, Vernonia cinerea and Atalantia ceylanica on a high fat diet induced metabolic dysfunction-associated steatotic liver disease mouse model Anuththara Upamali Abeykoon, Madhavi Priyanka Paranagama, Kavindra Kumara Wijesundera, Onela Canith Pathirana, Thilini Anupama Mahakapuge, Jayantha Rajapakse BMC Complementary Medicine and Therapies.2025;[Epub] CrossRef
Pruritus and Fatigue in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Study of Turkish Patients From the Global NASH/MASH Registry Yusuf Yilmaz, Caglayan Keklikkiran, Andrei Racila, Maria Stepanova, Zobair M. Younossi Clinical and Translational Gastroenterology.2025; 16(6): e00844. CrossRef
Omega-3 polyunsaturated fatty acids and nonalcoholic fatty liver disease in adults: A meta-analysis of randomized controlled trials Su Jin Kim, Su Hwan Cho, Jae Moon Yun Clinical Nutrition.2025; 50: 164. CrossRef
Hyperuricemia—Especially “Metabolic Hyperuricemia”—Is Independently Associated with a Higher Risk of Steatotic Liver Disease Janis Timsans, Jenni Kauppi, Vappu Rantalaiho, Anne Kerola, Kia Hakkarainen, Mika Paldanius, Hannu Kautiainen, Markku Kauppi Metabolites.2025; 15(6): 356. CrossRef
Gut microbiota modulation by Traditional Chinese Medicine: a translational strategy for metabolic dysfunction-associated steatotic liver disease Ting Zhou, Ziwen Jin, Rilei Jiang, Weiwei Li Frontiers in Pharmacology.2025;[Epub] CrossRef
Oleocanthalic acid improves MASH features via a NOX1-dependent mechanism Yahima Frion-Herrera, Ilaria Zanotto, Martina Colognesi, Anna Signor, Doretta Cuffaro, Adriana Chilin, Marco Macchia, Giovanni Marzaro, Maria Digiacomo, Daniela Gabbia, Sara De Martin European Journal of Pharmacology.2025; 1002: 177847. CrossRef
Projected Trends in Metabolic Dysfunction–Associated Steatotic Liver Disease Mortality Through 2040 Xinrong Zhang, Sovann Linden, Charles R. Levesley, Xinyuan He, Zhanpeng Yang, Scott D. Barnet, Ramsey Cheung, Fanpu Ji, Mindie H. Nguyen JAMA Network Open.2025; 8(6): e2516367. CrossRef
Association of behavioral factors, liver function and NAFLD: Bayesian Mendelian randomization Lei Pu, Cheng Pu, Xiaoyan Zhang Nutrition & Metabolism.2025;[Epub] CrossRef
Adding salt to foods and risk of metabolic dysfunction-associated steatotic liver disease and other chronic liver diseases Shunming Zhang, Zhenyu Huo, Yan Borné, Emily Sonestedt, Lu Qi European Journal of Nutrition.2025;[Epub] CrossRef
A Gastroenterologist’s Approach to Improving Metabolic Health in MASLD Eyad Abdulrazzak, Imad Alabdul Razzak, Mazen Noureddin, Hirsh D. Trivedi Journal of Clinical Gastroenterology.2025; 59(8): 713. CrossRef
Elucidating the mechanistic interplay of AMPK and Nrf2 in MASLD: A focus on dietary phytochemical modulation of lipid and redox homeostasis Cindy H.J. Yu, H.P. Vasantha Rupasinghe Biochemical and Biophysical Research Communications.2025; 777: 152300. CrossRef
Association between the dietary index for gut microbiota and all-cause/cardiovascular mortality in patients with metabolic dysfunction-associated steatotic liver disease Wenhao Wu, Jiacheng Cheng, Zebin Hou, Qi Yan, Xiaojuan Wang, Junhua He, Yikun Zhu, Jin Li Diabetology & Metabolic Syndrome.2025;[Epub] CrossRef
Steatosis non-invasive tests accurately predict metabolic dysfunction-associated steatotic liver disease, while fibrosis non-invasive tests fall short: Validation in U.S. adult population Ayesha Sualeheen, Sze-Yen Tan, Robin M. Daly, Ekavi Georgousopoulou, Gavin Abbott, Stuart K. Roberts, Jacob George, Elena S. George Clinics and Research in Hepatology and Gastroenterology.2025; 49(7): 102649. CrossRef
A nomogram incorporating clinical and laboratory indicators for predicting metabolic dysfunction‐associated fatty liver disease in newly diagnosed type 2 diabetes patients Tingting Li, Yao Wang, Shengnan Zhao, Yuliang Cui, Zhenzhen Qu Journal of Diabetes Investigation.2025; 16(10): 1919. CrossRef
Liver disease trends in the Asia-Pacific region for the next 50 years Shuichiro Shiina, Javkhlan Maikhuu, Qing Deng, Terguunbileg Batsaikhan, Lariza Marie Canseco, Maki Tobari, Hitoshi Maruyama, Hiroaki Nagamatsu, Diana Alcantara-Payawal, Rino Gani, Yi-Hsiang Huang, Tawesak Tanwandee, Giovanni Galati, Yoon Jun Kim Clinical and Molecular Hepatology.2025; 31(3): 671. CrossRef
Association of APOC3 and PNPLA3 genetic polymorphism in adult Pakistani population with non-alcoholic fatty liver disease Muhammad Masroor, Zeba Haque, Haya Anwar, Farina Hanif, Waqas Ahmed Farooqui Human Gene.2025; 45: 201453. CrossRef
Analysis of the Mitochondrial Dynamics in NAFLD: Drp1 as a Marker of Inflammation and Fibrosis Maël Padelli, Jocelyne Hamelin, Christophe Desterke, Mylène Sebagh, Raphael Saffroy, Claudio Garcia Sanchez, Audrey Coilly, Jean-Charles Duclos-Vallée, Didier Samuel, Antoinette Lemoine International Journal of Molecular Sciences.2025; 26(15): 7373. CrossRef
Exploring the role of xanthine oxidase and aldehyde oxidase in metabolic dysfunction-associated steatotic liver disease (MASLD) Neha Gupta, Kavita Singh Journal of Molecular Histology.2025;[Epub] CrossRef
Guideline-directed medical strategies for the co-management of heart failure and metabolic dysfunction-associated steatotic liver disease Jacob J. Gries, Bing Chen, Meena B. Bansal, Mario Rodriguez, Saleh A. Alqahtani, Paul N. Brennan, Chim C. Lang, W. H. Wilson Tang, Jeffrey V. Lazarus, Chayakrit Krittanawong Communications Medicine.2025;[Epub] CrossRef
Liver sinusoidal endothelial cells: Central mediators of MASLD pathogenesis and sepsis susceptibility Yanying Wu, Wenyi Le, Huali Zhang, Yaxi Zhu Life Sciences.2025; 379: 123879. CrossRef
The Impact of Menopausal Hormone Therapy on Liver and Biliary Tract Health A. O. Bueverov, N. I. Tapilskaya Russian Journal of Gastroenterology, Hepatology, Coloproctology.2025; 35(3): 104. CrossRef
Translating Trial to Treatment: A Scoping Review of Resmetirom First Year in Real-World Use for Moderate to Advanced Fibrosis in Metabolic Dysfunction-Associated Steatohepatitis Kanika Vats, Mohammad Mazhar Alam Cureus.2025;[Epub] CrossRef
Placebo Effect on Changes in Magnetic Resonance-based Endpoints in Patients With MASH: Systematic Review and Meta-analysis Matheus Souza, Lubna Al-Sharif, Samira M. Khalil, Ivanna Diaz Journal of Clinical and Experimental Hepatology.2025; 15(6): 103173. CrossRef
Automated Detection of Non‐Alcoholic Fatty Liver Disease Using Histopathological Images: A Systematic Review Hamed Zamanian, Ahmad Shalbaf, Maryam Parvizi, Roohallah Alizadehsani, Ru‐San Tan, U. Rajendra Acharya WIREs Data Mining and Knowledge Discovery.2025;[Epub] CrossRef
Patatin-Like Phospholipase Domain-Containing Protein 3 (PNPLA3) rs738409 Variant and Non-Alcoholic Fatty Liver Disease Risk in Vietnamese Working-Age Adults: A Case-Control Study with Metabolic Insights Ha Nguyen, Duong Hoang Huy Le, Thinh Nguyen, Hung Cao Dinh, Tuan Nguyen Clinical and Experimental Gastroenterology.2025; Volume 18: 191. CrossRef
Xiaoyao San's dual efficacy in NAFLD and depression: Unraveling the mechanisms via network pharmacology and multi-omics Yunxiao Liu, Xiaomei Ding, Ayesha Younas, Xiaoning Sun, Xiaofen Ni, Shuanghu Wang, Jiaojian Lv, Zhiyong Li, Chuxiao Shao Phytomedicine.2025; 147: 157221. CrossRef
Burden and trends of nonalcoholic steatohepatitis-related liver cancer in China: A population-based observational study using GBD 2021 data Meng-Xiang Xiang, Peng Yan, Bin Lan, Jiang-Bei Deng, Jie Tan Medicine.2025; 104(37): e44515. CrossRef
Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications Xuan Trong Truong, Dae Ho Lee Diabetes & Metabolism Journal.2025; 49(5): 964. CrossRef
Sex Differences in MASLD After Age 50: Presentation, Diagnosis, and Clinical Implications Ilaria Milani, Maria Eugenia Parrotta, Luca Colangeli, Marianna Chinucci, Simonetta Palleschi, Barbara Rossi, Paolo Sbraccia, Alessandro Mantovani, Frida Leonetti, Valeria Guglielmi, Danila Capoccia Biomedicines.2025; 13(9): 2292. CrossRef
The impact of the Mediterranean diet on liver steatosis and fibrosis in patients with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease Simona Cernea, Danusia Onișor, Andrada Larisa Roiban Acta Marisiensis - Seria Medica.2025; 71(3): 188. CrossRef
Managing MASLD Through Preventive Hepatology: Integrating Policy Reform, Public Health and Personalised Care Zobair M. Younossi, Vincent Wai‐Sun Wong, Emmanuel A. Tsochatzis, Laurent Castera, Michael Betel, Linda Henry, Shira Zelber Sagi Liver International.2025;[Epub] CrossRef
Enzyme-responsive oleoylethanolamide-releasing nanomedicine for sustained liver delivery and therapeutic improvement in early-stage metabolic dysfunction-associated steatohepatitis (MASH) Yuanyuan Ding, Babita Shashni, Yukio Nagasaki Journal of Controlled Release.2025; 387: 114256. CrossRef
Effect of Varying Degrees of Hepatic Impairment on the Pharmacokinetics of Ervogastat, a Diacylglycerol Acyltransferase 2 (DGAT2) Inhibitor, and Clesacostat, an Acetyl‐CoA Carboxylase (ACC) Inhibitor Manoli Vourvahis, Arthur J. Bergman, Adam G. Ogden, Jim Hughes, James R. Gosset, Amit S. Kalgutkar, Neeta B. Amin The Journal of Clinical Pharmacology.2025; 65(12): 1876. CrossRef
Prevalence of metabolic dysfunction-associated fatty liver disease among health check-up attendees: A retrospective study conducted in Vietnam Ngan Lam Lu, Huong Tu Lam, Thong Duy Vo World Journal of Gastroenterology.2025;[Epub] CrossRef
The global cardiovascular–liver–metabolic syndemic: epidemiology, trends and challenges Nicholas W. S. Chew, Anurag Mehta, Rachel Goh, Jaycie Koh, Yiming Chen, Bryan Chong, Mark Y. Chan, Muhammad Shahzeb Khan, Mark D. Muthiah, Javed Butler, Arun J. Sanyal, Laurence S. Sperling Nature Reviews Cardiology.2025;[Epub] CrossRef
The pathogenesis of metabolic dysfunction-associated steatotic liver disease and nucleoside reverse transcriptase inhibitors (NRTIs) -based HIV-antiretroviral regimens: A comprehensive narrative review Marilize Horn, Nontobeko Gumede, Mlindeli Gamede Biomedicine & Pharmacotherapy.2025; 192: 118633. CrossRef
Metabolic Dysfunction–Associated Steatotic Liver Disease in Pregnancy Hannah W. Han, Peter S. Marcus, Tse-Ling Fong Obstetrical & Gynecological Survey.2025; 80(10): 647. CrossRef
Prevalence of Fibrosis and Applicability of Lab-based Noninvasive Tests From Primary to Tertiary Care Georg Semmler, Paul Thöne, Jan Embacher, Philipp Hruska, Lucie Simonis, Katharina Stopfer, Laurenz Fritz, Fiona Köck, Lorenz Balcar, Benedikt S. Hofer, Bernhard Wernly, Sophie Gensluckner, Michael Strasser, Andreas Völkerer, Katrine Lindvig, Maja Thiele, Clinical Gastroenterology and Hepatology.2025;[Epub] CrossRef
The emerging phenotype of nonalcoholic fatty liver disease in lean individuals: what’s different? Priyankar Dey Frontiers in Endocrinology.2025;[Epub] CrossRef
Repurposing levothyroxine for managing metabolic dysfunction-associated steatotic liver disease Leonidas H. Duntas, Stergios A. Polyzos, Ulrike Gottwald-Hostalek, Bogumila Urgatz, Paul M. Yen Endocrine.2025; 90(3): 1043. CrossRef
Menopause May Partially Explain Age-related Increased Risk of MASLD Fibrosis: A Causal Mediation Analysis Itunu O. Sokale, Yan Liu, Hashem B. El-Serag, Fasiha Kanwal, Aaron P. Thrift, Maya Balakrishnan Clinical Gastroenterology and Hepatology.2025;[Epub] CrossRef
Triglyceride-cholesterol-body weight index associated with the risk of metabolic dysfunction-associated steatotic liver disease: a population-based cross-sectional study Li Fan, Yongkang Su, Yue Chen, Ling Xu, Hairong Huang, Chunsheng Lu, Jia Peng, Yingbin Sun, Min Jia Frontiers in Nutrition.2025;[Epub] CrossRef
The Basics of Metabolic Dysfunction–Associated Steatotic Liver Disease for Cardiologists Muhammad Shahzeb Khan, Syed Sarmad Javaid, Amreen Dinani, Kara Wegermann, Ambarish Pandey, Ankeet S. Bhatt, Mark Muthiah, Harriette G.C. Van Spall, Faiez Zannad, Javed Butler, Michael L. Volk, Marat Fudim JACC.2025; 86(20): 1861. CrossRef
Extracellular Matrix Microstructures Directly Regulate Glutathione Bioavailability in Human Hepatocytes John A. Terrell, Chengpeng Chen Biomacromolecules.2025; 26(12): 8475. CrossRef
Improving surgical treatments for hepatocellular carcinoma Abdullah K. Malik, Daniel Geh, Thomas R. Jeffry Evans, Pierce K. H. Chow, Derek A. Mann, Steven A. White Nature Reviews Gastroenterology & Hepatology.2025;[Epub] CrossRef
Analysis of Health-Related Quality of Life and Its Influencing Factors Among Patients with Non-Alcoholic Fatty Liver Disease in Hangzhou, China: A Cross-Sectional Study Han Fei, Kexin Lv, Jiayin Xu, Haojie Hao, Yidan Quan, Junping Shi, Wei Zhang Metabolic Syndrome and Related Disorders.2025; 23(7): 329. CrossRef
CD209a regulates metabolic dysfunction-associated steatotic liver disease development through macrophage STAT3 signaling pathway Yishu Chen, Jiaming Zhou, Chenxi Tang, Pengwei Zhu, Zixin Xu, Xin Song, Jie Zhang, Li Cen, Hang Zeng, Yini Ke, Youming Li, Yi Chen, Jinghua Wang Cellular & Molecular Biology Letters.2025;[Epub] CrossRef
MASLD: Lipotoxicity and Imaging Parallels from Liver Steatosis to Kidney Injury Sarmis Marian Săndulescu, Denisa Ștefania Ghiga, Diana Rodica Tudorașcu, Daniela Larisa Săndulescu, Adrian Mită, Marinela Cristiana Urhuț, Citto-Iulian Taisescu Life.2025; 15(12): 1805. CrossRef
Metabolic dysfunction-associated steatotic liver disease in Egypt: Epidemiology, risk factors and management challenges Walaa Abdelhamed, Mona Amin, Imam Waked, Mohamed El-Kassas World Journal of Gastroenterology.2025;[Epub] CrossRef
Folic Acid Combined with Melatonin Might Prevent Hepatic Steatosis by Alleviating Endoplasmic Reticulum Stress to Promote Lipid Droplet Lipolysis in High-Fat Diet-Fed Mice Dan Sun, Yanzhen Ma, Yixian Bai, Xue Bai, Weiheng Liu, Lin Du, Peng Wang, Xi Liang, Hui Liang, Huaqi Zhang Nutrients.2025; 17(23): 3641. CrossRef
From liver to gut: the hidden gastrointestinal impact of pediatric metabolic dysfunction-associated steatotic liver disease Gianmario Forcina, Vittoria Frattolillo, Maria De Cesare, Assunta Floriano, Rosamaria Palma, Federica Casamassima, Mario Bartiromo, Pierluigi Marzuillo, Emanuele Miraglia del Giudice, Anna Di Sessa Expert Review of Gastroenterology & Hepatology.2025; 19(12): 1329. CrossRef
Prevalence and severity of MASLD and fibrosis using transient elastography: A cross-sectional screening in Lower Mainland, British Columbia, Canada Kai Zhu, Harjot Bedi, Daljeet Chahal, Josh Kim, Eric M Yoshida, Peter Kwan Canadian Liver Journal.2025; 8(4): 580. CrossRef
Transcriptomic Changes Underlying the Anti-Steatotic Effects of DHA Supplementation in Aged Obese Female Mice Álvaro Pejenaute Martínez de Lizarrondo, Paula Martín-Climent, María Martínez-Rubio, Jesús Saborido-Gavilán, Neira Sáinz, Elisa Félix-Soriano, Miriam Samblas, Mónica Alfonso-Núñez, Elizabeth Guruceaga, M. Pilar Lostao, Pedro González-Muniesa, María J. Mor International Journal of Molecular Sciences.2025; 26(23): 11689. CrossRef
Antioxidant Capacity and Inhibition of Lipid Accumulation Effect of Baccharis articulata and Citrus sinensis Infusions Francisco Gualdieri, Gabriela Rocha, Ruben Iacono, Mauricio De Marzi, Liliana N. Guerra Plant Foods for Human Nutrition.2025;[Epub] CrossRef
Hepatic steatosis in postmenopausal women is characterized by distinct serum extracellular vesicle proteomic signatures Patrick Pirrotte, Brooke Lovell, Siobán D. Harlow, Carrie A. Karvonen-Gutierrez, Michelle M. Hood, Ignazio S. Piras, Xiumei Wu, Melissa N. Martinez, Ritin Sharma, Krystine Garcia-Mansfield, Maya Willey, Johanna K. DiStefano BMC Medicine.2025;[Epub] CrossRef
NEDD4L knockdown reduced lipid accumulation in non-alcoholic fatty liver disease by promoting the activity of PI3K/AKT signaling pathway Ju Zhou, Wu Li, Xiaowei Chi, Dingchun Li, Chunxia Yang, Zhiwen Duan European Journal of Medical Research.2025;[Epub] CrossRef
The liver manifestation of metabolic syndrome is now called MASLD - an up-to-date view of the most common liver disease today Václav Šmíd, Karel Dvořák Vnitřní lékařství.2024; 70(1): E8. CrossRef
Circulating fatty acids and risk of severe non-alcoholic fatty liver disease in the UK biobank: a prospective cohort of 116 223 individuals Pan Zhuang, Yang Ao, Xiaohui Liu, Hao Ye, Haoyu Li, Xuzhi Wan, Yu Zhang, Jingjing Jiao Food & Function.2024; 15(20): 10527. CrossRef
The impact of gut microbiome-targeted therapy on liver enzymes in patients with nonalcoholic fatty liver disease: an umbrella meta-analysis Ehsan Amini-Salehi, Soheil Hassanipour, Mohammad-Hossein Keivanlou, Milad Shahdkar, Mahdi Orang Goorabzarmakhi, Azin Vakilpour, Farahnaz Joukar, Mohammad Hashemi, Nazila Sattari, Mohammadreza Javid, Fariborz Mansour-Ghanaei Nutrition Reviews.2024; 82(6): 815. CrossRef
A global action agenda for turning the tide on fatty liver disease Jeffrey V. Lazarus, Henry E. Mark, Alina M. Allen, Juan Pablo Arab, Patrizia Carrieri, Mazen Noureddin, William Alazawi, Naim Alkhouri, Saleh A. Alqahtani, Quentin M. Anstee, Marco Arrese, Ramon Bataller, Thomas Berg, Paul N. Brennan, Patrizia Burra, Grac Hepatology.2024; 79(2): 502. CrossRef
Stemness markers in hepatocellular carcinoma of Eastern vs. Western population: Etiology matters? Caecilia HC Sukowati, Korri El-Khobar, Chyntia Olivia Maurine Jasirwan, Juferdy Kurniawan, Rino Alvani Gani Annals of Hepatology.2024; 29(1): 101153. CrossRef
Can liquid biopsies for MASH help increase the penetration of metabolic surgery? A narrative review Lidia Castagneto-Gissey, Stefan R. Bornstein, Geltrude Mingrone Metabolism.2024; 151: 155721. CrossRef
Reply Jong Woo Hahn, Soeun Kim, Dong Keon Yon Clinical Gastroenterology and Hepatology.2024; 22(4): 905. CrossRef
Metabolic dysfunction associated steatotic liver disease: Current practice, screening guidelines and management in the primary care setting Udita Gupta, Thomas Ruli, Danyaal Buttar, Mohamed Shoreibah, Meagan Gray The American Journal of the Medical Sciences.2024; 367(2): 77. CrossRef
Exclusive liquor and cocktail consumption is associated with at‐risk fibrosis among nonheavy alcohol users with metabolic dysfunction‐associated steatotic liver disease Peng‐sheng Ting, Wei‐Ting Lin, Chiung‐Kuei Huang, Hui‐Yi Lin, Tung‐Sung Tseng, Po‐Hung Chen Alcohol: Clinical and Experimental Research.2024; 48(1): 88. CrossRef
Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease James A Thomas, Bradley J Kendall, Hashem B El-Serag, Aaron P Thrift, Graeme A Macdonald The Lancet Gastroenterology & Hepatology.2024; 9(2): 159. CrossRef
Compensated Advanced Chronic Liver Disease and Steatosis in Patients with Type 2 Diabetes as Assessed through Shear Wave Measurements and Attenuation Measurements Mislav Barisic-Jaman, Marko Milosevic, Viktoria Skurla, David Dohoczky, Josip Stojic, Petra Dinjar Kujundzic, Maja Cigrovski Berkovic, Ana Majic-Tengg, Ana Matijaca, Tomo Lucijanic, Mirjana Kardum-Pejic, Vlatka Pandzic Jaksic, Srecko Marusic, Ivica Grgure Biomedicines.2024; 12(2): 323. CrossRef
Molecular Insights of Nonalcoholic Fatty Liver Disease Pathogenesis Reham Mohammed Dawood, Ghada Maher Salum, Mai Abd El-Meguid, Basma EL-sayed Fotouh Journal of Interferon & Cytokine Research.2024; 44(3): 111. CrossRef
Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings Chul-min Lee, Eileen L. Yoon, Mimi Kim, Bo-Kyeong Kang, Seon Cho, Eun-Hee Nah, Dae Won Jun Hepatology.2024; 79(6): 1393. CrossRef
Proanthocyanidins-Based Synbiotics as a Novel Strategy for Nonalcoholic Fatty Liver Disease (NAFLD) Risk Reduction Wasitha P. D. W. Thilakarathna, H. P. Vasantha Rupasinghe Molecules.2024; 29(3): 709. CrossRef
Suv39h1 contributes to activation of hepatic stellate cells in non-alcoholic fatty liver disease by enabling anaerobic glycolysis Xiaoyan Wu, Yuzhou Shen, Yufei Meng, Jinsi Chen, Yongchen Zhang, Sheng Zeng, Huihui Xu Life Sciences.2024; 341: 122498. CrossRef
Self-management behaviours in adults with non-alcoholic fatty liver disease: a cross-sectional survey from China Run Zhou, Binbin Zhang, Wei Zhang, Tingting Kong, Jie Fu, Jie Li, Junping Shi BMJ Open.2024; 14(2): e078333. CrossRef
Updated Insights into Probiotics and Hepatobiliary Diseases Xiaoyu Xu, Cheng Zhang, Guoyi Tang, Ning Wang, Yibin Feng Biomedicines.2024; 12(3): 515. CrossRef
Disparities among ethnic groups in mortality and outcomes among adults with MASLD: A multicenter study Majd B. Aboona, Claire Faulkner, Pooja Rangan, Cheng Han Ng, Daniel Q. Huang, Mark Muthiah, Moises I. Nevah Rubin, Ma Ai Thanda Han, Michael B. Fallon, Donghee Kim, Vincent L. Chen, Karn Wijarnpreecha Liver International.2024; 44(6): 1316. CrossRef
Optimizing surveillance of low-risk metabolic dysfunction associated steatotic liver disease using transient elastography Harish Gopalakrishna, Gayatri B. Nair, Roham Salman Roghani, Natarajan Ravendhran, Yaron Rotman European Journal of Gastroenterology & Hepatology.2024; 36(4): 476. CrossRef
Implications of Protein and Sarcopenia in the Prognosis, Treatment, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Avneet Singh, Adam Buckholz, Sonal Kumar, Carolyn Newberry Nutrients.2024; 16(5): 658. CrossRef
Proposal of a Novel Serological Algorithm Combining FIB-4 and Serum M2BPGi for Advanced Fibrosis in Nonalcoholic Fatty Liver Disease Sang Yi Moon, Yang Hyun Baek, Se Young Jang, Dae Won Jun, Ki Tae Yoon, Young Youn Cho, Hoon Gil Jo, Ae Jeong Jo Gut and Liver.2024; 18(2): 283. CrossRef
Comprehensive meta-analysis reveals distinct gene expression signatures of MASLD progression Ignazio S Piras, Johanna K DiStefano Life Science Alliance.2024; 7(6): e202302517. CrossRef
Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis Michael H. Le, David M. Le, Thomas C. Baez, Hansen Dang, Vy H. Nguyen, KeeSeok Lee, Christopher D. Stave, Takanori Ito, Yuankai Wu, Yee Hui Yeo, Fanpu Ji, Ramsey Cheung, Mindie H. Nguyen Clinical and Molecular Hepatology.2024; 30(2): 235. CrossRef
In response to: Steatotic liver disease-know your enemies Michael H. Le, Linda Henry, Mindie H. Nguyen Clinical and Molecular Hepatology.2024; 30(2): 284. CrossRef
Antiviral therapy response in patients with chronic hepatitis B and fatty liver: A systematic review and meta‐analysis Fajuan Rui, Elizabeth Garcia, Xinyu Hu, Wenjing Ni, Qi Xue, Yayun Xu, Xiaoming Xu, Junping Shi, Mindie H. Nguyen, Ramsey C. Cheung, Jie Li Journal of Viral Hepatitis.2024; 31(7): 372. CrossRef
The impact of county-level food access on the mortality and post-transplant survival among patients with steatotic liver disease Yutaka Endo, Diamantis I. Tsilimigras, Mujtaba Khalil, Jason Yang, Selamawit Woldesenbet, Kazunari Sasaki, Ashley Limkemann, Austin Schenk, Timothy M. Pawlik Surgery.2024; 176(1): 196. CrossRef
Omics-based biomarkers as useful tools in metabolic dysfunction-associated steatotic liver disease clinical practice: How far are we? Julieta Trinks, María F Mascardi, Adrián Gadano, Sebastián Marciano World Journal of Gastroenterology.2024; 30(14): 1982. CrossRef
Burden of liver disease in Brazil, 1996–2022: a retrospective descriptive study of the epidemiology and impact on public healthcare João Sérgio Fonseca Guimarães, Jordana Almeida Mesquita, Thais Yuki Kimura, Ana Luíza Matos Oliveira, M. Fatima Leite, André Gustavo Oliveira The Lancet Regional Health - Americas.2024; 33: 100731. CrossRef
The Global Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among Patients With Type 2 Diabetes Zobair M. Younossi, Pegah Golabi, Jillian Kallman Price, Soroor Owrangi, Nagashree Gundu-Rao, Romona Satchi, James M. Paik Clinical Gastroenterology and Hepatology.2024; 22(10): 1999. CrossRef
Molecular Genealogy of Metabolic-associated Hepatocellular Carcinoma Takahiro Kodama, Tetsuo Takehara Seminars in Liver Disease.2024; 44(02): 147. CrossRef
Association between biological aging and the risk of mortality in individuals with non-alcoholic fatty liver disease: A prospective cohort study Haili Wang, Zhenqiu Liu, Hong Fan, Chengnan Guo, Xin Zhang, Yi Li, Xinyu Han, Tiejun Zhang Archives of Gerontology and Geriatrics.2024; 124: 105477. CrossRef
An Electronic Health Record Model for Predicting Risk of Hepatic Fibrosis in Primary Care Patients Aaron P. Thrift, Theresa H. Nguyen Wenker, Kyler Godwin, Maya Balakrishnan, Hao T. Duong, Rohit Loomba, Fasiha Kanwal, Hashem B. El-Serag Digestive Diseases and Sciences.2024; 69(7): 2430. CrossRef
Liver disease in patients with transfusion-dependent β-thalassemia: The emerging role of metabolism dysfunction-associated steatotic liver disease Nikolaos Fragkou, Efthimia Vlachaki, Ioannis Goulis, Emmanouil Sinakos World Journal of Hepatology.2024; 16(5): 671. CrossRef
Single nucleotide polymorphisms in the cannabinoid CB2 receptor: Molecular pharmacology and disease associations Tahira Foyzun, Maddie Whiting, Kate K. Velasco, Jessie C. Jacobsen, Mark Connor, Natasha L. Grimsey British Journal of Pharmacology.2024; 181(15): 2391. CrossRef
Diagnostic indicators and lifestyle interventions of metabolic-associated fatty liver disease Tianzhu Chen, Xiang Qin, Jianping Jiang, Beihui He Frontiers in Nutrition.2024;[Epub] CrossRef
A global survey on the use of the international classification of diseases codes for metabolic dysfunction-associated fatty liver disease Huai Zhang, Giovanni Targher, Christopher D. Byrne, Seung Up Kim, Vincent Wai-Sun Wong, Luca Valenti, Myer Glickman, Jaime Ponce, Christos S. Mantzoros, Javier Crespo, Henning Gronbaek, Wah Yang, Mohammed Eslam, Robert J. Wong, Mariana Verdelho Machado, M Hepatology International.2024; 18(4): 1178. CrossRef
Association between hemoglobin and non-alcoholic fatty liver disease (NAFLD) in United States adults: Results from NHANES 2017–2020 Kang Yao, Zheng Chen, Wei Zhou, Zhihua Liu, Wei Cui Preventive Medicine Reports.2024; 44: 102798. CrossRef
Mapping the global research landscape on nonalcoholic fatty liver disease and insulin resistance: A visualization and bibliometric study Sa'ed H Zyoud, Omar E Hegazi, Samer O Alalalmeh, Muna Shakhshir, Faris Abushamma, Shadi Khilfeh, Samah W Al-Jabi World Journal of Hepatology.2024; 16(6): 951. CrossRef
Diagnostic performance of CT/MRI LI-RADS v2018 in non-cirrhotic steatotic liver disease Jennie Cao, Andy Shon, Luke Yoon, Aya Kamaya, Justin R. Tse European Radiology.2024; 34(12): 7622. CrossRef
Persons with metabolic dysfunction‐associated steatotic liver disease are at increased risk of severe depression Hanne Åström, Ying Shang, Hannes Hagström, Axel Wester Liver International.2024; 44(10): 2551. CrossRef
An examination of global research trends for exploring the associations between the gut microbiota and nonalcoholic fatty liver disease through bibliometric and visualization analysis Sa’ed H. Zyoud, Samer O. Alalalmeh, Omar E. Hegazi, Muna Shakhshir, Faris Abushamma, Samah W. Al-Jabi Gut Pathogens.2024;[Epub] CrossRef
Mechanism of epigallocatechin gallate in treating non-alcoholic fatty liver disease: Insights from network pharmacology and experimental validation Danting Mao, Jianwei Guo, Kunli Yang, Fan Yang, Jiaojiao Peng, Xu Jia, Ziren Luo, Lu Liu, Enjie Yang, Rui Tang, Haitao Lan, Qian Zheng Biochemical and Biophysical Research Communications.2024; 734: 150424. CrossRef
Dysfunctional VLDL metabolism in MASLD Urko M. Marigorta, Oscar Millet, Shelly C. Lu, José M. Mato npj Metabolic Health and Disease.2024;[Epub] CrossRef
A systematic review and meta-analysis of randomized controlled trials: effects of mediterranean diet and low-fat diet on liver enzymes and liver fat content of NAFLD Yalan Xiong, Xinyu Shi, Xinying Xiong, Shenyu Li, Hanhua Zhao, Hualing Song, Jianying Wang, Lei Zhang, Shengfu You, Guang Ji, Baocheng Liu, Na Wu Food & Function.2024; 15(16): 8248. CrossRef
Food inequity and insecurity and MASLD: burden, challenges, and interventions Shira Zelber-Sagi, Patrizia Carrieri, Juan M. Pericàs, Dana Ivancovsky-Wajcman, Zobair M. Younossi, Jeffrey V. Lazarus Nature Reviews Gastroenterology & Hepatology.2024; 21(10): 668. CrossRef
A Precision Medicine Guided Approach to the Utilization of Biomarkers in MASLD Nimish Thakral, Hailemichael Desalegn, Luis Antonio Diaz, Daniel Cabrera, Rohit Loomba, Marco Arrese, Juan Pablo Arab Seminars in Liver Disease.2024; 44(03): 273. CrossRef
Resmetirom and Metabolic Dysfunction-Associated Steatohepatitis: Perspectives on Multidisciplinary Management from Global Healthcare Professionals Kahei Au, Ming-Hua Zheng, Wei-Jei Lee, Omar M. Ghanem, Kamal Mahawar, Asim Shabbir, Carel W. le Roux, Giovanni Targher, Christopher D. Byrne, Yusuf Yilmaz, Luca Valenti, Giada Sebastiani, Sombat Treeprasertsuk, Hannah Xiaoyan Hui, Nasser Sakran, Manoel Ga Current Obesity Reports.2024; 13(4): 818. CrossRef
Immune system dysregulation in the pathogenesis of non-alcoholic steatohepatitis: unveiling the critical role of T and B lymphocytes Merve Cebi, Yusuf Yilmaz Frontiers in Immunology.2024;[Epub] CrossRef
Synergistic association of sodium-glucose cotransporter-2 inhibitor and metformin on liver and non-liver complications in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease Xianhua Mao, Xinrong Zhang, Leslie Kam, Nicholas Chien, Rongtao Lai, Ka-Shing Cheung, Man-Fung Yuen, Ramsey Cheung, Wai-Kay Seto, Mindie H Nguyen Gut.2024; 73(12): 2054. CrossRef
Pathophysiological Relationship between Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Therapeutic Approaches Shifat-E Ferdous, Jessica M. Ferrell International Journal of Molecular Sciences.2024; 25(16): 8731. CrossRef
Novel insights into causal effects of maternal nonalcoholic fatty liver disease on adverse pregnancy outcomes: evidence from Human Genetics and Mendelian Randomization Study Qiuyan Luo, Guoting Liu, Qiulan Li, Jinghong Lu, Wenjing Zheng, Yukui Huang, Cun Li European Journal of Clinical Nutrition.2024; 78(12): 1041. CrossRef
Role of Growth Hormone Therapy in Metabolic-Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis Deep Dutta, Lakshmi Nagendra, Ritin Mohindra, Saptarshi Bhattacharya, Ameya Joshi, ABM Kamrul-Hasan Indian Journal of Endocrinology and Metabolism.2024; 28(4): 336. CrossRef
Meta-analysis of randomized controlled trials of the effects of synbiotics, probiotics, or prebiotics in controlling glucose homeostasis in non-alcoholic fatty liver disease patients Siqi Ding, Qing Hong, Yuanyue Yao, Minwen Gu, Jie Cui, Wenhui Li, Jian Zhang, Chengcheng Zhang, Jinchi Jiang, Yonghong Hu Food & Function.2024; 15(19): 9954. CrossRef
The Clínica Universidad de Navarra-Body Adiposity Estimator index is a reliable tool for screening metabolic dysfunction-associated steatotic liver disease: an analysis from a gender perspective Chao Wang, Xin Huang, Shiming He, Maobin Kuang, Guobo Xie, Guotai Sheng, Yang Zou Lipids in Health and Disease.2024;[Epub] CrossRef
Systemic treatment of hepatocellular carcinoma secondary to non-alcoholic fatty liver disease Karolina Rzeniewicz, Rohini Sharma World Journal of Clinical Oncology.2024; 15(11): 1394. CrossRef
Invited Commentary: Radiology at the Forefront in the Fight against Metabolic Dysfunction–associated Steatotic Liver Disease Sudhakar K. Venkatesh RadioGraphics.2024;[Epub] CrossRef
Visceral Obesity and Its Association with Severe Coronary Artery Calcification in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease Min Kyu Kang, Jeung Eun Song, Young Oh Kweon, Won Young Tak, Soo Young Park, Yu Rim Lee, Jung Gil Park Diagnostics.2024; 14(20): 2305. CrossRef
Metabolic-associated fatty liver disease is less effective in predicting mortality than non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease: Letter to the editor on “Prognosis of biopsy-confirmed metabolic dysfun Yixuan Zhu, Xiaoyan Ma, Wenjing Ni, Yee Hui Yeo, Junping Shi, Jie Li Clinical and Molecular Hepatology.2024; 30(4): 974. CrossRef
Incidence rates of hepatocellular carcinoma based on risk stratification in steatotic liver disease for precision medicine: A real-world longitudinal nationwide study Rongtao Lai, Scott Barnett, Xinrong Zhang, Leslie Yeeman Kam, Ramsey Cheung, Qing Xie, Mindie H. Nguyen, Gilaad G. Kaplan PLOS Medicine.2024; 21(10): e1004479. CrossRef
DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease Amal Magdy, Hee-Jin Kim, Hanyong Go, Jun Min Lee, Hyun Ahm Sohn, Keeok Haam, Hyo-Jung Jung, Jong-Lyul Park, Taekyeong Yoo, Eun-Soo Kwon, Dong Hyeon Lee, Murim Choi, Keon Wook Kang, Won Kim, Mirang Kim Clinical and Molecular Hepatology.2024; 30(4): 824. CrossRef
Modelo Wistar de doença hepática gordurosa não alcoólica: indução por fonte natural de colesterol Maysa Ortolani Matera, Gabriel dos Santos, Maíza Pelissari Migliorini, Karyn Maria Wenglarek, Thais de Lima da Silva, Flávia Cristina Colmenero, Isabela Hess Justus, Bruna Karas, Marcelo de Oliveira Dreweck, Sérgio Ossamu Ioshii, Mario Claudio Soares Stur Cuadernos de Educación y Desarrollo.2024; 16(11): e6263. CrossRef
Machine-Learning Application for Predicting Metabolic Dysfunction-Associated Steatotic Liver Disease Using Laboratory and Body Composition Indicators Fatemeh Masaebi, Mehdi Azizmohammad Looha, Morteza Mohammadzadeh, Vida Pahlevani, Mojtaba Farjam, Farid Zayeri, Reza Homayounfar Archives of Iranian Medicine.2024; 27(10): 551. CrossRef
Coexisting metabolic dysfunction-associated steatotic liver disease exacerbates in-hospital outcomes in patients with heat stroke Ping Zhang, Guo Tang, Hongguang Gao, Tianshan Zhang, Sha Yang, Tao Cheng, Rong Yao Frontiers in Medicine.2024;[Epub] CrossRef
Trends in Hepatocellular Carcinoma Mortality Rates in the US and Projections Through 2040 Sikai Qiu, Jiangying Cai, Zhanpeng Yang, Xinyuan He, Zixuan Xing, Jian Zu, Enrui Xie, Linda Henry, Custis R. Chong, Esther M. John, Ramsey Cheung, Fanpu Ji, Mindie H. Nguyen JAMA Network Open.2024; 7(11): e2445525. CrossRef
Doença hepática gordurosa não alcoólica experimental induzida por dieta rica em colesterol Maíza Pellissari Migliorini, Gabriel dos Santos, Maysa Ortolani Matera, Karyn Maria Wenglarek, Thais de Lima da Silva, Jaqueline Meert Parlow, Isabela Hess Justus, Flávia Cristina Colmenero, Marcelo de Oliveira Dreweck, Sérgio Ossamu Ioshii, Mário Cláudio Cuadernos de Educación y Desarrollo.2024; 16(11): e6598. CrossRef
Comparative analysis of NAFLD-related health videos on TikTok: a cross-language study in the USA and China Hongyu Wu, Jialun Peng, Shengwei Li, Xiong Ding, Tao Zhong, Qilong Zhai, Changjie Du, Jiajun Yuan, Can Cai, Jinzheng Li BMC Public Health.2024;[Epub] CrossRef
Contribution of Sex Differences to Development of Cardiovascular Disease in Metabolic-Associated Steatotic Liver Disease (MASLD) Lucy C. Taylor, Gertrude Arthur, Marcella de Carvalho Cruz, David E. Stec, Olufunto O. Badmus International Journal of Translational Medicine.2024; 4(4): 782. CrossRef
Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non‐alcoholic fatty liver disease Ho Soo Chun, Minjong Lee, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Yong‐Ho Lee, Ji‐Hye Kim, Seung Up Kim Liver International.2023; 43(3): 608. CrossRef
Correspondence on Editorial regarding “Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations” Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn Clinical and Molecular Hepatology.2023; 29(1): 185. CrossRef
Clinical Implications of Cardiac Symptoms and Electrocardiographic Abnormalities for Advanced Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease Min-Kyu Kang, Min-Cheol Kim Medicina.2023; 59(2): 375. CrossRef
The independent effect of exercise on biopsy-proven non-alcoholic fatty liver disease: A systematic review George Chen, Bubu Banini, Albert Do, Joseph K. Lim Clinical and Molecular Hepatology.2023; 29(Suppl): S319. CrossRef
Global incidence and prevalence of nonalcoholic fatty liver disease Margaret LP Teng, Cheng Han Ng, Daniel Q. Huang, Kai En Chan, Darren JH Tan, Wen Hui Lim, Ju Dong Yang, Eunice Tan, Mark D. Muthiah Clinical and Molecular Hepatology.2023; 29(Suppl): S32. CrossRef
Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments Sang Bong Ahn Clinical and Molecular Hepatology.2023; 29(Suppl): S150. CrossRef
The effects of moderate alcohol consumption on non-alcoholic fatty liver disease Hyunwoo Oh, Won Sohn, Yong Kyun Cho Clinical and Molecular Hepatology.2023; 29(Suppl): S261. CrossRef
Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis Yi-wen Shi, Jian-Gao Fan Clinical and Molecular Hepatology.2023; 29(Suppl): S228. CrossRef
Risk Stratification for Sarcopenic Obesity in Nonalcoholic Fatty Liver Disease Rongtao Lai, Mindie H. Nguyen Clinical Gastroenterology and Hepatology.2023; 21(11): 2984. CrossRef
The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review Young-Joo Jin Clinical and Molecular Hepatology.2023; 29(2): 414. CrossRef
The growing burden of non-alcoholic fatty liver disease on mortality Ju-Yeon Cho, Won Sohn Clinical and Molecular Hepatology.2023; 29(2): 374. CrossRef
Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease—Current Background, Hopes, and Perspectives Georgiana-Diana Cazac, Cristina-Mihaela Lăcătușu, Gabriela Ștefănescu, Cătălina Mihai, Elena-Daniela Grigorescu, Alina Onofriescu, Bogdan-Mircea Mihai Metabolites.2023; 13(5): 581. CrossRef
The Role of Choline, Soy Isoflavones, and Probiotics as Adjuvant Treatments in the Prevention and Management of NAFLD in Postmenopausal Women Johanna K. DiStefano Nutrients.2023; 15(12): 2670. CrossRef
Mechanisms Linking Metabolic-Associated Fatty Liver Disease (MAFLD) to Cardiovascular Disease Olufunto O. Badmus, Terry D. Hinds, David E. Stec Current Hypertension Reports.2023; 25(8): 151. CrossRef
Cardiovascular outcomes among persons with HIV and nonalcoholic fatty liver disease Sepiso K. Masenga, Lweendo Muchaili, Benson M. Hamooya AIDS.2023; 37(8): 1329. CrossRef
Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis Bryan Tan, Xin-Hui Pan, Han Shi Jocelyn Chew, Rachel Sze Jen Goh, Chaoxing Lin, Vickram Vijay Anand, Ethan Cheng Zhe Lee, Kai En Chan, Gwyneth Kong, Christen En Ya Ong, Hui Charlotte Chung, Dan Yock Young, Mark Y. Chan, Chin Meng Khoo, Anurag Mehta, Mark International Journal of Obesity.2023; 47(8): 677. CrossRef
Non-Alcoholic Fatty Liver Disease: Translating Disease Mechanisms into Therapeutics Using Animal Models Amina Basha, Sarah C. May, Ryan M. Anderson, Niharika Samala, Raghavendra G. Mirmira International Journal of Molecular Sciences.2023; 24(12): 9996. CrossRef
Transient elastography with controlled attenuation parameter versus two-dimensional shear wave elastography with attenuation imaging for the evaluation of hepatic steatosis and fibrosis in NAFLD Jung Wook Seo, Youe Ree Kim, Jong Keon Jang, So Yeon Kim, Young Youn Cho, Eun Sun Lee, Dong Ho Lee Ultrasonography.2023; 42(3): 421. CrossRef
The impact of concomitant metabolic dysfunction-associated fatty liver disease on adverse outcomes in patients with hepatitis B cirrhosis: a propensity score matching study Xinyu Wang, Shuhang Wei, Yingnan Wei, Xueqi Wang, Feng Xiao, Yuemin Feng, Qiang Zhu European Journal of Gastroenterology & Hepatology.2023; 35(8): 889. CrossRef
Lifestyle interventions in nonalcoholic fatty liver disease Zobair M. Younossi, Shira Zelber-Sagi, Linda Henry, Lynn H. Gerber Nature Reviews Gastroenterology & Hepatology.2023; 20(11): 708. CrossRef
The latest evidence on the impact of fatty liver on liver-related outcomes and mortality in chronic hepatitis B Xianhua Mao, Lung Yi Mak, Wai-Kay Seto Clinical and Molecular Hepatology.2023; 29(3): 690. CrossRef
Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study Matina Kouvari, Laura Valenzuela-Vallejo, Valentina Guatibonza-Garcia, Stergios A. Polyzos, Yixiang Deng, Michail Kokkorakis, Melih Agraz, Sophia C. Mylonakis, Angeliki Katsarou, Ornella Verrastro, Georgios Markakis, Mohammed Eslam, Georgios Papatheodorid Metabolism.2023; 147: 155666. CrossRef
Ca2+ signaling and the Hippo pathway: Intersections in cellular regulation Samar Sayedyahossein, Louise Thines, David B. Sacks Cellular Signalling.2023; 110: 110846. CrossRef
The first external validation of the Dallas steatosis index in biopsy-proven Non-alcoholic fatty liver Disease: A multicenter study Matina Kouvari, Sophia C. Mylonakis, Angeliki Katsarou, Laura Valenzuela-Vallejo, Valentina Guatibonza-Garcia, Michail Kokkorakis, Ornella Verrastro, Giulia Angelini, Georgios Markakis, Mohammed Eslam, Jacob George, Georgios Papatheodoridis, Geltrude Ming Diabetes Research and Clinical Practice.2023; 203: 110870. CrossRef
Uniting to defeat steatotic liver disease: A global mission to promote healthy livers and healthy lives Aleksander Krag, Maria Buti, Jeffrey V. Lazarus, Alina M. Allen, Jacqueline Bowman, Patrizia Burra, Giacomo Donnini, Ajay Duseja, Manal H. El-Sayed, Amalia Gastaldelli, Ben Hainsworth, Tom H. Karlsen, Michael Kessler, Marko Korenjak, Henry E. Mark, Jake P Journal of Hepatology.2023; 79(5): 1076. CrossRef
Unraveling the link between insulin resistance and Non-alcoholic fatty liver disease (or metabolic dysfunction-associated steatotic liver disease): A Narrative Review Fateme Ziamanesh, Mehdi Mohammadi, Sholeh Ebrahimpour, Ozra Tabatabaei-Malazy, Asieh Mosallanejad, Bagher Larijani Journal of Diabetes & Metabolic Disorders.2023; 22(2): 1083. CrossRef
Global health burden of cirrhosis and other chronic liver diseases (CLDs) due to non-alcoholic fatty liver disease (NAFLD): A systematic analysis for the global burden of disease study 2019 Jie Li, Qingzhi Wang, Wenjing Ni, Chuan Liu, Zhihui Li, Xiaolong Qi Global Transitions.2023; 5: 160. CrossRef
The Impact of Intermittent Fasting on Non-Alcoholic Fatty Liver Disease in Older Adults: A Review of Clinicaltrials.gov Registry Nasser Alorfi, Ahmed Ashour Diabetes, Metabolic Syndrome and Obesity.2023; Volume 16: 3115. CrossRef
Update on the Obesity Epidemic: After the Sudden Rise, Is the Upward Trajectory Beginning to Flatten? Chrysi Koliaki, Maria Dalamaga, Stavros Liatis Current Obesity Reports.2023; 12(4): 514. CrossRef
Metabolic-Dysfunction-Associated Steatotic Liver Disease—Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments Hidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, Sakura Iida, Hisayuki Katsuyama International Journal of Molecular Sciences.2023; 24(20): 15473. CrossRef
An integrated gene-to-outcome multimodal database for metabolic dysfunction-associated steatotic liver disease Timothy J. Kendall, Maria Jimenez-Ramos, Frances Turner, Prakash Ramachandran, Jessica Minnier, Michael D. McColgan, Masood Alam, Harriet Ellis, Donald R. Dunbar, Gabriele Kohnen, Prakash Konanahalli, Karin A. Oien, Lucia Bandiera, Filippo Menolascina, An Nature Medicine.2023; 29(11): 2939. CrossRef
Association of nonalcoholic fatty liver disease and growth hormone deficiency: a systematic review and meta-analysis Tingting Kong, Yunpeng Gu, Lei Sun, Run Zhou, Jie Li, Junping Shi Endocrine Journal.2023; 70(10): 959. CrossRef
Magnetic resonance elastography-based prediction model for hepatic decompensation in NAFLD: A multicenter cohort study Beom Kyung Kim, Jaclyn Bergstrom, Rohan Loomba, Nobuharu Tamaki, Namiki Izumi, Atsushi Nakajima, Ramazan Idilman, Mesut Gumussoy, Digdem K. Oz, Ayse Erden, Emily Truong, Ju Dong Yang, Mazen Noureddin, Alina M. Allen, Rohit Loomba, Veeral Ajmera Hepatology.2023; 78(6): 1858. CrossRef
The Impact and Burden of Dietary Sugars on the Liver Helaina E. Huneault, Ana Ramirez Tovar, Cristian Sanchez-Torres, Jean A. Welsh, Miriam B. Vos Hepatology Communications.2023;[Epub] CrossRef
Transcriptomics of MASLD Pathobiology in African American Patients in the Washington DC Area † Tanmoy Mondal, Coleman I. Smith, Christopher A. Loffredo, Ruth Quartey, Gemeyel Moses, Charles D. Howell, Brent Korba, Bernard Kwabi-Addo, Gail Nunlee-Bland, Leanna R. Rucker, Jheannelle Johnson, Somiranjan Ghosh International Journal of Molecular Sciences.2023; 24(23): 16654. CrossRef
Racial and ethnic differences and the role of unfavorable social determinants of health across steatotic liver disease subtypes in the United States Pedro Ochoa-Allemant, Jorge A. Marrero, Marina Serper Hepatology Communications.2023;[Epub] CrossRef
The Influence of Coffee on Reducing Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes: A Review Manpreet Kaur, Shanmathi Murugesan, Sachpreet Singh, Katherine N Uy, Jasjeet Kaur, Navina Mann, Rajneet K Sekhon Cureus.2023;[Epub] CrossRef
International diet quality index and revised diet quality index relationship with non-alcoholic fatty liver disease: a case-control study Narjes Najibi, Mitra Kazemi Jahromi, Farshad Teymoori, Hossein Farhadnejad, Ammar Salehi-Sahlabadi, Parvin Mirmiran BMC Gastroenterology.2023;[Epub] CrossRef
Developmental Programming: Impact of Prenatal Exposure to Bisphenol A on Senescence and Circadian Mediators in the Liver of Sheep Giuliana Motta, Soundara Viveka Thangaraj, Vasantha Padmanabhan Toxics.2023; 12(1): 15. CrossRef
Nonalcoholic fatty liver disease: a review of physiology, treatments, and market outlook Pammar Aryan Advances in Tissue Engineering & Regenerative Medicine: Open Access.2023; 9(1): 42. CrossRef
Non-Alcoholic Fatty Liver Disease, Atherosclerosis, and Cardiovascular Disease in Asia Yohwan Lim, Seogsong Jeong, Myunghee Hong, Hyun Wook Han Reviews in Cardiovascular Medicine.2023;[Epub] CrossRef
First
Prev
